تقييم إقتصادي لعلاجات إزالة الحديد من الجسم لمرضى الثلاسيميا في الضفة الغربية - فلسطين by Abdeen, Layali Hani
  
Economic Evaluation of Iron Chelation Therapies for 
Thalassemia Patients in the West Bank- Palestine 
 
 ةفضلا ًف اٍمٍسلاثلا ىضرمل مسجلا نم دٌدحلا ةلازا تاجلاعل يداصتقا مٍٍقت
ةٍبرغلا- نٍطسلف  
 
 
Submitted by: Layali Hani Abdeen 
Date of discussion: April 29
th
 2009 
The committee: Dr. Awad Mataria 
                                 Dr. Muhammad Nasser 
                       Dr. Rana Khatib 
 
 
This Thesis was submitted in partial fulfillment of the requirements for 
the Master‟s degree in Economics from the Faculty of Graduate Studies 
at Birzeit University. Palestine 
 
  
II 
 
 
 
Economic Evaluation of Iron Chelation Therapies for 
Thalassemia Patients in the West Bank- Palestine 
 
 ةفضلا ًف اٍمٍسلاثلا ىضرمل مسجلا نم دٌدحلا ةلازا تاجلاعل يداصتقا مٍٍقت
ةٍبرغلا- نٍطسلف  
 
 
 
Submitted by: Layali Hani Abdeen 
Date of discussion: April 29
th
 2009 
The committee: Dr. Awad Mataria 
                                 Dr. Muhammad Nasser 
                       Dr. Rana Khatib 
 
 
 
  
III 
Acknowledgments 
 
I would like to extend my appreciation to all the people that had helped me in 
completing and gathering the information needed to complete the thesis, the 
Thalassemia Patients‟ Friends Association, especially Ms. Jihad Abu Gosh and Ms. 
Rasha Qadi, Ministry of Health, Dr. Bashar Karmi, Dr. Qusai Dawabsheh and Dr. 
Hisham Darwish. 
I would also like to thank the nurses from the TPFA who helped me in administering 
the questionnaires, without their efforts it would have been impossible to gather the 
information in such a short period. 
Last but not least I would like to extend my gratitude and appreciation to a really 
dedicated supervisor Dr. Awad Mataria, and to all my family for their support, 
especially my husband Rateb.  
 
 
 
 
 
 
  
IV 
Table of Contents 
Acknowledgments .................................................................................................................... III 
Abbreviations: .......................................................................................................................... VI 
CBA – Cost Benefit Analysis .................................................................................................. VI 
CEA – Cost Effectiveness Analysis ......................................................................................... VI 
CMA – Cost Minimization Analysis ....................................................................................... VI 
Abstract: .................................................................................................................................. VII 
1. Introduction ........................................................................................................................ 1 
1.1. Health Economics ..................................................................................................... 1 
1.2. Thalassemia in Palestine ........................................................................................... 2 
1.3. Problem statement ..................................................................................................... 6 
2. Literature review .............................................................................................................. 11 
2.1. Economic Evaluation .............................................................................................. 11 
2.2. Cost Analysis: ......................................................................................................... 21 
2.3. Thalassemia ............................................................................................................. 23 
2.4. Management of thalassemia .................................................................................... 24 
2.5. Economic Evaluation of iron chelating management ............................................. 32 
3. Methodology ..................................................................................................................... 33 
3.1. Sampling ................................................................................................................. 33 
3.2. Theoretical framework ............................................................................................ 34 
4. Results ............................................................................................................................... 51 
4.1. Qualitative results ................................................................................................... 51 
4.2. Quantitative results ................................................................................................. 58 
5. Discussion .......................................................................................................................... 93 
  
V 
5.1. CEA ......................................................................................................................... 93 
5.2. CUA ........................................................................................................................ 94 
5.3. CBA ........................................................................................................................ 98 
6. Recommendations: ......................................................................................................... 101 
7. References ....................................................................................................................... 104 
8. Appendix: ........................................................................................................................ 112 
Appendix 1: ....................................................................................................................... 112 
Appendix 2: ....................................................................................................................... 131 
Appendix 3: ....................................................................................................................... 139 
Appendix 4: ....................................................................................................................... 143 
 
 
 
 
 
 
 
 
 
  
VI 
 
 
Abbreviations: 
 
CBA – Cost Benefit Analysis 
CEA – Cost Effectiveness Analysis 
CMA – Cost Minimization Analysis 
CUA – Cost Utility Analysis 
DFO – Deferioxamine/ Desferal 
DFX – Deferasirox/ Exjade 
FGD – Focus Group Discussion 
GDP – Gross Domestic Product 
ICER – Incremental Cost Effectiveness Ratio 
ICUR – Incremental Cost Utility Ratio 
L1 – Deferiprone / Ferriprox 
MOH – Ministry of Health 
NIS – New Israeli Shekel 
QoL – Quality of Life 
TPFA – Thalassemia Patients Friends Association 
USD – Unites States Dollar 
WTP – Willingness to Pay 
  
VII 
 
 
 
Abstract: 
Decreasing the amount of iron in the blood is crucial for thalassemia patients as they 
get regular blood transfusions for their treatment, and as a result iron accumulates in 
the body damaging vital organs such as the liver and heart, which ultimately leads to 
the death of the patient.  
In Palestine, thalassemia patients undergo the difficult and painful infusion of a drug 
known as Deferoxamine (Desferal®/ DFO) that rids the body from excess iron. The 
drawback of such management strategy consists in its invasive character, where a 
needle, attached to a small battery-operated infusion pump, is worn under the skin 
overlying the stomach or legs, 5 to 7 times a week for up to 12 hours in each 
administration. Deferoxamine binds with iron in a process called “chelation”, leading 
to the elimination of the excess iron from the body. This treatment is found 
cumbersome by many patients, implying low adherence from their side with the 
management regimen, thus limiting its effectiveness in real life settings. 
Consequently, the oral iron chelators have been introduced to help patients get rid of 
excess iron in a convenient matter. The two „Oral Iron Chelators‟ are: 
1- Deferiprone: Ferriprox® / L1 
2- Deferasirox: Exjade®/ DFX 
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However, these oral chelators have not yet been introduced in the Palestinian context.  
This paper will investigate whether an introduction of the oral iron chelators will 
be more cost effective and whether they enhance Quality of Life (QoL) for 
patients in Palestine. 
Three analytical approaches were used to assess the costs and consequences 
associated with each of the treatment strategies. Firstly, a cost-effectiveness analysis 
was conducted. Here, the comparison between the different medications was in terms 
of incremental cost effectiveness ratio (ICER), and the effect that was considered is 
the intermediate outcome of reduced iron in the body, which was measured through 
serum ferritin levels.  From the Ministry of Health perspective DFX had lower ICER 
of NIS 392,384.7 per percentage reduction in serum ferritin levels than L1 when 
compared to DFO. From the patient perspective however, oral chelators strongly 
dominated the Desferal, while from the society perspective DFX had also lower 
ICER than L1 when compared to DFO. 
Along this a cost-utility analysis was used to incorporate the „Quality of Life‟ of the 
patients under the different medications, where oral chelators strongly dominated 
over DFO in the age category of over 4 years old, while in the societal perspective the 
ICUR was NIS 153,370/ QALY gained for the age group below or equal to 4 years 
old, and NIS 151,832.1/ QALY gained for the age group above 4 years old. 
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The third approach which is cost benefit analysis was used in an attempt to measure 
the effectiveness gained from oral chelators monetarily through estimating directly 
and indirectly the willingness to pay for the oral chelators using a contingent 
valuation and a conjoint analysis respectively. The net social benefit was highly 
positive in both cases.  
KEY WORDS: cost-effectiveness; cost utility; quality of life; conjoint analysis; 
thalassemia; oral chelators. 
 
 
 
1. Introduction 
1.1. Health Economics 
Health economics is concerned with the connection between health and the 
resources which are consumed in promoting it (Johansson and Jonson 1999). 
Resources do not include only money, rather people, materials and time which 
could have been put to some other use (Witter, 2000). 
 Since resources are scarce, choices must and will be made concerning their 
deployment, thus allocating them to the most efficient programme or measure 
(Drummond et al. 2005). In order to measure the efficiency of such programs 
there are different methods. The most common is economic evaluation, where it 
provides important information to decision makers especially in the absence of 
effective markets. Economic evaluation is defined as the “comparative analysis of 
alternative courses of action in terms of both their costs and consequences” 
(Drummond et al. 2005). Therefore the basic task of any economic evaluation is 
to identify, measure, value and compare the costs and consequences of the 
alternatives being considered. There are different types of economic evaluation, 
depending on the outcome of each procedure; they are (Drummond et al. 2005): 
1- Cost minimization analysis (CMA). 
2- Cost effectiveness analysis (CEA). 
3- Cost benefits analysis (CBA). 
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4- Cost utility analysis (CUA) 
 
The paper will attempt to use these techniques in assessing different management 
strategies of thalassemia patients in Palestine, and try to induce the most efficient 
strategy that enables to maximize the benefits to the patients and the society as a 
whole. 
1.2. Thalassemia in Palestine 
Thalassemia is the name of a group of genetic blood disorders, in which the 
production of normal hemoglobin is partly, or completely, suppressed due to 
defective synthesis of one or more of its component globin chains (Gomber et al. 
2004). To elaborate, hemoglobin is the main constituent of human red blood cells, 
responsible for carrying, and delivering, oxygen molecules to aliment all body 
cells. It consists of several combinations of two different proteins, Alpha and 
Beta; in addition to an iron moiety located in the central part of the molecule. In 
the case of thalassemia, one or more of the globins are inadequately produced – or 
even not produced at all (Thalassemia Organization 2006). If the mal-production 
affects the alpha-chain, then the disorder is known as alpha-thalassemia. 
Similarly, if the defected component is the beta-chain, then the resulting condition 
is beta-thalassemia (Gomber et al. 2004). 
In Palestine, beta thalassemia is the most common whether in its major, 
intermediate or minor form. There are 662 patients diagnosed with either major or 
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intermediate beta thalassemia in 2007, 412 in the West Bank and 250 in Gaza. 
The annual increase in thalassemia between Palestinians was 20%-25% till 2000. 
This has led the Palestinian Government to take safety measurements such as 
applying the law that forces the couples to be examined for positive thalassemia 
before getting married and prohibiting any couple from getting married if proven 
so. Consequently, this has led to a decrease in the incidence of the disease 
between the Palestinians to reach 3.5% in the years to follow. 
In Palestine thalassemia is mainly managed through regular blood transfusions to 
be done once or twice a month for a major thalassemic patient. In addition, 
patients are also subject to another management regimen aiming to reduce iron 
overload; i.e. excess iron accumulation, which results from frequent blood 
transfusions. In Palestine, thalassemia patients undergo the difficult and painful 
infusion of a drug known as Deferoxamine (Desferal
®
) that rids the body from 
excess iron (Darwish 2006). The drawback of such management strategy is 
represented by its invasive character, whereby a needle, attached to a small 
battery-operated infusion pump, is worn under the skin overlying the stomach or 
legs, 5 to 7 times a week for up to 12 hours in each administration (Hidmi 2007). 
Deferoxamine (DFO) binds with iron in a process called “chelation”, leading to 
the elimination of the excess iron from the body (Hershko 2005). This treatment 
is found cumbersome by many patients, implying low adherence from their side 
with the management regimen (Cappellini 2005; Porter 2005). 
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The treatment regimen is financially supported by the Ministry of Health (MOH) 
in cooperation with the Thalassemia Patients Friends Association (TPFA). TPFA 
provides the blood through encouraging and providing blood donors, in addition 
to providing a program for blood transfusions, which enables the patients to have 
systematic blood transfusions. The TPFA also provides the following (Nabulsi 
2006): 
 A nurse in each hospital.   
 Register patients and their families in the health insurance which is provided 
freely by the MOH. 
 Donating pumps necessary for the medicine injections and providing their 
maintenance which is only done outside the country in Jordan. 
 Providing free periodical examinations for the hormones, heart, sight and 
hearing for the patients. Also they provide the quarterly, half yearly and 
yearly examinations needed by the patients through the corporation of several 
physicians who volunteer to supervise such examinations. 
 TFPA has also established treatment centers in Hebron, Nablus and Tulkarem. 
 In parallel the TFPA also provides a psychological program for the patients. 
This program supports the patients who feel isolated from the society through 
establishing educational programs in the society to identify the disease and 
limits its incidence by ensuring that the couples do adhere with the law of 
examining before marriage. 
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It must be noted that in Palestine there is another institution that works beside the 
TPFA known as The National Institution for Blood Diseases “Abiqrat”. This 
institution provides the patients with the opportunities to have bone marrow 
transplantations, which is considered the ultimate treatment regimen worldwide as 
it eliminates the disease and the patient can survive normally. However such a 
management is not affordable to all patients due to the following reasons: 
 If the patients suffer from any side effects from thalassemia, such as 
enlargement of the spleen, this would lead to dangerous repercussions on the 
patients‟ life, thus the success of this management regimen is very low in such 
cases. 
 Patients under 10 years old have higher success probabilities than older 
patients. 
 Such management also depends on the availability of bone marrow donors, on 
the compatibility between the donors‟ body and the patients‟ body, and the 
overall health of the donor. 
The costs of such operations are high; however, Abiqrat provides such 
management for free. The institution has done 24 operations since 2003 for 
patients from the West Bank and Gaza Strip. Today, 22 cases revealed to be 
successful, whereas the other two suffered major complications leading to the 
death of one patient after two months from the operation. 
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1.3. Problem statement 
As delineated, thalassemia patients in Palestine undergo the difficult and painful 
infusion of Deferrioxamine (Desferal®) that rids the body from excess iron. The 
drawback of such management strategy consists in its invasive character, where a 
needle, attached to a small battery-operated infusion pump, is worn under the skin 
overlying the stomach or legs, 5 to 7 times a week for up to 12 hours in each 
administration. This mechanism of chelation results in low compliance from 
patients thus affecting morbidity and mortality rates, in addition to its effects on 
the Quality of Life of the patients that results in increased costs on society. 
The total cost of iron management strategy, when assessed from the perspective 
of the health care provider, is mainly driven by the cost of the Desferal needle that 
averages around NIS 15.3/ needle and patients usually need around 2 needles a 
day. The costs of infusion pumps and their maintenance cost (in the local context 
such a pump costs between USD1,000 and USD1,500, and remains functional for 
a period of 5-6 years) are high but they are not borne by the Ministry of Health 
since these pumps usually come as donations when acquiring the medication 
(Hidmi 2007). However, it must be noted that in Palestine there are only 200 
pumps available for an estimated number of 600 patients (Abu Ghosh 2007). 
Apart from the direct medical costs mainly borne by the health care providers, 
such treatment strategy has direct non-medical, indirect and intangible costs when 
assessed from the patients‟ perspective. This is due to the impact it has on 
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patients‟ every day, remunerated and non-remunerated, activities and „Quality of 
Life‟. A recent graduate seminar paper, prepared by one of the Master in 
Economics students at Birzeit University, had already uncovered the high burden 
that the thalassemia condition and such its treatment strategies impose on 
Palestinian thalassemia patients, in terms of physical difficulties associated with 
the treatment procedure and the psychological burdens (Nabulsi 2006).   
Desferal (DFO) has proved to be efficacious in preventing and managing iron 
overload, however, adherence with this treatment regimen is a major issue from 
the patients‟ perspective, thus limiting its effectiveness in real life settings (Porter 
2005). Consequently, oral iron chelators have been introduced to help patients get 
rid of excess iron in a convenient matter (Porter 2005; Hershko 2005). Today, 
there are two available „Oral Iron Chelators‟ and they are: 
3- Deferiprone: Ferriprox®. 
4- Deferasirox: Exjade® 
Accordingly, and amongst the three available management strategies of iron 
overload in thalassemic patients subject to regular blood transfusions, a question 
repeatedly posed about which management strategy represents the most efficient 
strategy in terms of its cost effectiveness, cost utility and cost benefit, as related to 
Palestinian patients from the perspective of the patients, Ministry of Health and 
the society as a whole? 
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Such a problem is associated with a number of sub-problems that the thesis will 
aim to tackle, such as cost calculations, obtaining scores for quality of life for 
thalassemic patients and extracting willingness to pay for oral chelators. 
Thus the analysis shall be conducted from the perspective of health care 
providers; and then challenged to assess the impact of incorporating a patients‟ 
perspective on the decision to be taken. Therefore the study will reflect the 
perspective of health care systems providers in the West Bank (MoH and TPFA) 
as well as the perspective of the patients. 
It is worth mentioning that the conduct of such analysis is verified for two 
reasons: 
1- the Palestinian MoH, with help from TPFA, is aiming to introduce one 
of the above mentioned Oral Iron Chelators, should their medical and 
economic values; e.g., cost-effectiveness and cost-utility, be 
ascertained.  
2- There are costs, efficacy/effectiveness and utility repercussion 
differentials between the two oral chelators and when compared to the 
currently used parental therapy. This makes it difficult to pinpoint the 
most cost-effective medication without a systematic inquiry and 
profound scientific analysis of the benefits and burdens associated 
with each of the therapies.  
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This Master Thesis shall help inform the decision of adopting, or not, any of these 
two new „Oral Iron Chelators‟ to replace the currently used parental 
Deferoxamine. 
The research endeavor will pass by the following steps: 
 A survey of the most popular databases such as: Medline and Hinari, will be 
carried out to extract relevant literature on the different clinical trials 
conducted to assess the consequences of the concerned management 
strategies. 
 The costs of each medication will be estimated using information provided 
by:  governmental and non-governmental bodies, any related organizations, 
the medical staff, and finally the patients themselves.  
 In order to assess the current „Quality of Life‟ of the thalassemia patients, a 
structured questionnaire will be administered on a selected sample of patients, 
using the one developed by Ratip et al, and recently tested in the Palestinian 
context by Nabulsi in 2006; the former has indeed been developed to assess 
the clinical and psychological burden of thalassemia (Tefler et al. 2005). 
However, the questionnaire will be validated in the local context through a 
focus group that will underlie the specificity of Palestine.  
 To indirectly asses WTP for oral chelators, a questionnaire will be 
administered for the patients where several scenarios shall be proposed to 
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analyze the patients‟ stated preferences about how they would behave in a 
hypothetical situation. Such a technique is known as the conjoint analysis, 
where it is based on the premises that any good or service can be described by 
its characteristics (attributes) and that the extent to which an individual values 
a good or a service depends on the levels of these characteristics (Ryan and 
Farrar 2000). 
 Cost-effectiveness, cost-utility and cost benefit analyses will be carried out, in 
order to help inform policies with regard to the most worthwhile strategy for 
Palestine.  
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2. Literature review 
2.1. Economic Evaluation 
There are four different full economic evaluations that distinguish from each 
other based on how the consequences of the programs being evaluated are 
measured and valued. These are: 
1- Cost Minimization Analysis (CMA): 
CMA is used when the consequences of the programs in consideration are 
exactly the same on all the dimensions of interest. Hence, the only difference 
between the different programs would be in the associated costs, leading the 
decision maker to choose the programmes with the least cost (Durmmond 
2005; Witter 2000).   
2- Cost Effectiveness Analysis(CEA): 
CEA is applied on programmes that have the same outcome of interest but 
may have different success in achieving this outcome as well as different 
costs. The decision about which programme to choose is made based on the 
additional resources needed to achieve enhancements in health outcomes. The 
comparison between the programs could be in the form of incremental cost 
per incremental unit effect such as incremental cost per life year gained or 
effects per unit of cost such as life years gained per extra dollar spent 
(Durmmond 2005; Donaldson and Shackley 1997a). It is worth noting that 
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life years gained are considered a final outcome of any medical intervention, 
however some clinical trials provide us with intermediate outcomes rather 
than a final outcome such as number of cases found or number of patients 
treated appropriately. These intermediate outcomes could be used in CEA as 
long as a link has been established between them and the final health output or 
in cases where the intermediate outcome is proven to have value per se 
(Durmmond 2005).  
3- Cost Utility Analysis (CUA): 
CUA is applied when researchers want to measure the outcome or value of 
any programme in utility terms. More importantly, CUA is used when 
valuation is done using „health state preferences‟ through the use of utility. 
Utility refers to the preferences individuals or society may have for any 
particular set of health outcomes. CUA is viewed as a useful term because it 
allows for quality of life adjustments to a given set of treatment outcomes, 
while providing a generic outcome measure for the comparison of costs and 
outcomes in different programmes. The results of CUA are expressed in terms 
of incremental cost per healthy year gained or incremental cost per Quality 
Adjusted Life Year (QALY) gained by undertaking one programme over the 
other, where QALY takes both the quantity and quality of life due to health 
care intervention. A score of 1 usually represents a perfect health and 0 
represents death (Durmmond 2005). 
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3.1. Measuring preferences: 
There are various methods to measure preferences: 
1- Rating scale and its variants is the simplest approach in measuring 
preferences, where respondents would be asked to rank health outcomes 
from most preferred to least preferred, and then place the outcomes on a 
scale with intervals between each outcome corresponding to differences in 
preferences. The scaling of such preferences has different variations where a 
rating scale refers to a scale of numbers (0-100), category rating consist of 
small number of categories (10 or 11) and subjects assume that they are 
equally spaced, and visual analogue scaling that consist of a line on a page 
with clearly defined end points. 
2- Standard gamble, usually used to measure chronic conditions and the subject 
is offered 2 alternatives, the first one is a treatment with 2 possible outcomes 
either the patient returns to a perfect health and lives for an additional t years 
(with probability p) or dies immediately (with a probability 1-p). Alternative 
2 however, would have a certain outcome of the chronic state under 
consideration for the rest of individuals‟ life. In this approach p is varied 
until the subject becomes indifferent between the two alternatives (Klose 
1999; Ryan et al 2003).  
3- Time trade off (TTO), was developed as a more easy technique compared to 
the standard gamble approach where a patient with chronic condition is given 
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2 alternatives: either state i for time t or healthy for a number of years x less 
than t followed then by death. The x is varied until the respondent is 
indifferent between the two alternatives (Diener et al, 1998). 
4- Pre scored multi attribute health status classification systems; this approach is 
more favorable than the previous three that are very time consuming and 
involve complex tasks in calculations. There are many systems that could be 
used in this approach such as: 
a- Quality of Well Being (QWB). 
b- Health Utilities Index (HUI). 
c- EuroQol (EQ-5D). 
d- World Health Organization QoL (WHO-100) 
 The above measurements (a-d) are used to obtain quality of life (QoL) 
weights in order to obtain a measurement for the QALY. 
In Palestine there have been several attempts to measure QoL for Palestinian 
patients through adapting international questionnaires and validating them in 
the local context. A study done by (Giacman et al 2007) has attempted to 
adapt the WHOQoL questionnaire and consequently has introduced new 
themes and aspects in measuring the QoL for the Palestinian population. A 
QoL score has also been estimated for post partum women in Palestine 
(Hammoudeh, 2008). 
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4.1. What is QoL? 
According to the World Health Organization (WHO), QoL is defined as “an 
individual‟s perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, 
standards and concerns. It is a broad ranging concept affected in a complex way 
by the persons‟ physical health, psychological state, personal beliefs, social 
relationships and their relationship to salient features of their environment.” 
Thus and according to the above definition, a questionnaire for measuring the 
QoL was developed by the WHO and is known as the WHOQOL-100 which is 
constructed from 100 questions and has an abbreviated version called the 
WHOQOL-BREF.  These two questionnaires have the following domains that 
help measure the QoL: 
-Physical Health 
-Psychological 
-Level of independence 
-Social relations 
-Environment 
-Spirituality/religion/personal beliefs 
However, Thalassemia patients encounter different domains and determinants that 
affect their QoL that are not measured/ reflected in the generic WHO versions or 
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any other versions for this matter that target the whole population rather than 
groups affected by specific diseases. Accordingly, Ratip et al. 1999 have 
developed another QoL questionnaire which is specific for thalassemia patients 
and measures the clinical and psychological burden of Thalassemia (Tefler et al 
2005). It constitutes the following themes that are expected to affect the QoL of 
the patient: 
-Impact of the diagnosis and treatment on family stability and family dynamics. 
-Feeling different. 
-Appearance. 
-Treatment. 
-Absent or delayed sexual development. 
-Complications. 
-Uncertainties about the future. 
Ratip Questionnaire has been adapted in several countries to measure the 
psychosocial burden of the disease on thalassemic patients. Such studies were 
conducted in USA (Sherman et al.1985; Woo et al. 1985), UK (Ratip and Modell 
1996; Tsiantis et al. 1996), Turkey (Canatan et el. 2003), Canada (Klein et al. 
1998), Italy (Di Palma et al. 1998; Politis et al. 1990; Tsiantis et al. 1996), 
Greece (Beratis 1993; Tsiantis 1990; Politis et al. 1990) and Lebanon (Der 
Kaloustian et al. 1987). An attempt has also been made to use this questionnaire 
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in Palestine by Nabulsi in 2006, however the questionnaire implemented was not 
the same as Ratips‟ and did not have the same layout rather it depended on the 
main themes outlined by Ratip et al.  
4- Cost Benefit Analysis: 
CBA is used in analyzing programmes that have multiple outcomes. In addition, 
any analyses that measure both costs and consequences in dollars terms is called 
cost – benefit analysis, consequently, outcomes are valued and not only measured 
in dollar terms. The results of such analysis might be stated either in the form of a 
ratio of dollar costs to dollar benefits or as a simple sum representing the net 
benefit (loss) of one programme over another, and the latter is usually more 
preferred than the former (Durmmond 2005). 
In CBA there are several ways to measure and value health outcomes in monetary 
terms: 
a- Human capital: this approach place monetary weights on healthy time using 
market wages rates (Klose 1999; Koopmanschap 1995) and the value of the 
programme is assessed in terms of the present value of future earnings. However 
such technique is accompanied with calculation difficulties due to imperfections 
in labor markets and also due to equity and welfare issues that are not considered 
in such an analysis (Drummond, 2005; Mishan, 1971). 
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b- Revealed preferences: this approach examines the relationship between particular 
health risks associated with each hazardous job and wage rates that individuals 
require to accept such a job (Durmmond 2005), this approach is based on 
individual preferences regarding the value of increased/decreased health risk as a 
trade off against increased/decreased income that represent all other goods and 
services the person may consume. However the weakness in such approach is in 
its high variations in valuations and estimations are very limited and job specific. 
c- Stated preferences of willingness to pay: WTP measure could be computed in two 
ways, either directly or indirectly. This method attempts to measure directly the 
maximum willingness to pay for non-marketed goods (health care programmes) 
through surveys that present consumers/ patients with various hypothetical 
scenarios about the programme evaluated. Accordingly, Klose 1999 defines 
contingent valuation as “a survey based, hypothetical and direct method used for 
eliciting a monetary value of a health care intervention”. This technique usually 
presents the health outcome as either improvements in health status or as 
attributes (Donaldson and Schackley 1997). The values revealed (consumer 
surplus) are then added across the individuals forming the basis for cost benefit 
calculus. The weakness in such technique comprises in the difficulties in 
measuring willingness to pay and the various debated and proposed methods in 
how to formulate the scenarios and questions to get a fairly “true” maximum 
willingness to pay figures. 
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When using the direct method to estimate WTP, there are several methods to 
elicit WTP measure, these vary from open ended questions, dichotomous 
approach (also known as take-it-or-leave-it (TIOLI), closed ended questions or 
referendum) and payment cards.  
The Open Ended (OE) approach present respondents with direct questions, where 
individuals will be asked to state their maximum willingness to pay for the 
product (Klose, 1999). 
In the dichotomous approach individuals are asked whether they would pay a 
specified amount for a given commodity, and responses vary between “Yes” and 
“No”. the bid amount is varied across respondents and the information obtained is 
whether the individual maximum WTP is above or below the bid amount (Ryan et 
al., 2004). 
 The Payment card technique present the individuals with a range of bids and 
asks them to circle the amount that represents the most they would be willing to 
pay (Ryan et al., 2004; Klose 1999; Donaldson et al., 1997). 
It is argued that the dichotomous approach and the payment card approach 
mimic real life settings (Donaldson et al., 1997) unlike the open ended (OE) 
questions approach. According to various studies (Donaldson et al., 1997; Ryan 
et al., 2004; Klose, 1999; Arow et al., 1993; Johansson et al., 1991) the concern 
with the OE approach is with its face validity as it does not reflect the way 
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individuals behave in a real market. In addition to that the approach has proven to 
mislead respondents as when they answer such questions they do not reveal their 
maximum willingness to pay (Donaldson et al., 1997; Ryan et al., 2004). Another 
problem associated with this method is that it produces a large number of non- 
responses since respondents may find such open questions difficult to answer 
(O‟Brien et al., 1996; Klose, 1999). 
d- Indirect methods comprises of tradeoffs individuals make between the 
consequence of the health intervention and the monetary value of this intervention 
in what is known as conjoint analysis that measures marginal rate of substitution 
between various attributes of a health care intervention and when entering the cost 
of the intervention indirect WTP could be derived (Ryan et al., 1999).   
 The first attempts to use conjoint analysis to measure consumer preferences were 
in market (Wardman 1988) and environmental economics (Swallow et al 1992; 
Opaluch et al 1993).  Conjoint analysis was then used extensively in health 
economics in the past 15 years (Ryan and Gerard 2003) to measure various issues 
such as the factors important to patients in the provision of health care systems 
(Ryan 1999). 
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2.2. Cost Analysis: 
This thesis has reviewed how consequences of heath programmes could be 
measured but in order also to perform a full economic evaluation cost analysis 
should be performed for each health intervention. To an economist the costs do 
not only include mere expenditures and out of the pocket money, rather it also 
includes the consumption of resources not necessarily priced in the markets such 
as patients‟ leisure time, any volunteer work, donations, etc. Accordingly, the 
main costs that should be considered in any health economic evaluations are 
(Durmmond 2005): 
a- Costs arising from the use of resources within the health sector, such as 
medications, hospitals, personals working in health sector…etc. 
b- Costs arising from resources use by patients and their families such as time spent 
by the patient and family when using certain health programme, private monetary 
contributions to the health care system and any expenditures also on 
transportations.  
c- Costs arising from resources use in other sectors. 
 
The consideration of any cost resources should stem from the perspective of the 
study whether it was done from a patients‟ perspective, health care system 
perspective or societal perspective as each perspective may include one cost but 
not the other. 
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In costs analysis it must be noted than when comparing two programmes, any 
common costs between the 2 programmes need not be calculated since they will 
not affect the choice of any programme. 
2.2.1. Calculating costs: 
In order to calculate costs one must measure the quantities of resources used and 
then assign the unit cost/price for each unit. The costs of resources are usually 
taken as market prices for such resources rather than opportunity costs of the 
resources used unless serious justifications were given to do otherwise 
(Durmmond 2005).  
As mentioned earlier, costs could include non priced resources such as patients 
leisure time or volunteer work. Volunteer work is usually valued using market 
wage rates. However leisure time lost could be valued either zero, average 
earnings or average overtime earnings and the most common approach is to value 
it at zero in the base case then analyze the impact of other estimates in a 
sensitivity analysis. 
2.2.2. Time frame used:   
The time frame the costs extends usually are not an arguable issue, however, the 
choice of follow up period when calculating a disease specific or therapy specific 
cost should not bias one intervention over the other as such costs could have a life 
time span even though the researcher could discount such future costs 
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2.3. Thalassemia 
Thalassemia minor (also known as Thalassemia trait) occurs when a person 
inherits one thalassemia gene from one of the parents and a normal hemoglobin 
gene from the other parent. If one parent has thalassemia trait and the other parent 
has the normal type of hemoglobin there is a 50% chance with each pregnancy 
that the baby will be born with thalassemia trait.  A person with thalassemia trait 
is usually healthy and might only have a mild anemia; consequently, most of 
those individuals are unaware that they have the disease (University of Rochester 
Medical Centre 2006).  
Thalassemia Major, however, occurs when a person inherits two thalassemia 
genes, one from each parent. If both parents have thalassemia trait, there is a 25% 
chance with each pregnancy that the baby will have thalassemia major. The baby 
with thalassemia major appears normal at birth. At the end of the first year the 
following symptoms occur:1- appetite and energy diminish, 2- The skin becomes 
pale, 3- certain bones of the face may become prominent, and 4- growth is slower 
than normal (University of Rochester Medical Centre 2006). 
Thalassemia intermedia, however, is somewhere between the minor state and 
the major state of thalassemia. Patients suffering from it could either be treated as 
major patients or as minor patients depending on the severity of the symptoms 
and it is most apparent between the siblings of the major patients (Yaish, 2007).  
  
24 
 Thalassemia minor patients could survive with occasional or in certain cases, 
with no need for blood transfusion at all. However, patients suffering thalassemia 
major needs regular blood transfusions to guarantee regular replacement of non 
functional red blood cells (RBC) that are necessary to maintain vital metabolic 
activities, and hence, keeping the individual alive. Given that no natural 
mechanism is available to eliminate the excess iron resulting from repeated 
transfusions, the iron cumulates in different tissues of the human body resulting in 
a condition known as “ iron overload” (Hershko 2005). Iron excess is known to 
be toxic to several body tissues and organs, especially, the liver and the heart. 
Moreover, if left unmanaged, the iron overload would ultimately result in 
patients‟ early death from organ failure (Hershko 2005). 
2.4. Management of thalassemia 
Treating “iron overload”: 
Iron chelating therapy is the only method available for preventing early death 
caused mainly by myocardial and hepatic iron toxicity as results of iron overload 
(Hershko 2002). There are three medications for iron chelating and they are: 
1- Desferrioxamine (DFO): Desferal® 
2- Deferiprone (L1): Ferriprox® 
3- Deferasirox (ICL 670/ DFX): Exjade® 
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Desferrioxamine: 
DFO is a hexadentate chelator with a very high and selective affinity for iron. 
One molecule of desferrioxamine binds one atom of iron forming a stable 
complex that can be excreted via the bile or in the urine (Hershko 2005). It must 
be noted that DFO has been in widespread clinical use for more than 35 years. 
Many clinical trials established the efficacy of DFO in reducing morbidity and 
mortality related to iron toxicity in thalassemia patients (Borgna, Pignati et al. 
1998; Hershko et al. 2004; Olivieri et al. 1997; Olivieri et al 1994). However the 
drawback of such management strategy consists of its invasive character, where a 
needle attached to a small battery- operated infusion pump, is worn under the skin 
overlying the stomach or legs 5 to 7 times a week for up to 12 hours in each 
administration (Olivieri et al 1994). 
Deferoxamine is known to be efficacious in preventing and treating iron overload 
when applied in expert centers; however, adherence with the treatment from the 
side of the patients is a major issue and can significantly limit its effectiveness in 
real life setting (Poter 2005).  
Therefore, the last two decades witnessed the introduction of new therapies 
worldwide in the form of „Oral Iron Chelators‟. The latter are used to help 
patients get rid of excess iron in a more convenient manner (Porter 2005 and 
Hershko 2005). Oral Iron Chelators are proven to limit further the mortality and 
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morbidity associated with the thalassemia condition (Piaga et al. 2003 and Cohen 
et al. 2003), due to a better adherence to the treatment strategy from the side of 
the patients (Al Refaie et al. 1992 and Neufeld 2006). This shall also culminate in 
an enhanced „Quality of Life‟ of the patients undergoing the treatment (Abetz el 
al. 2006). 
 Deferiprone: 
Deferiprone (L1, 1, 2-dimethyl-3- hydroxypyrid-4-one) has been available for 
approximately 20 years and has been approved in some countries as a second line 
treatment for patients who are unable to receive DFO or whose response to DFO 
treatment is unsatisfactory. Deferiprone is a bidentate, orally active chelator. It 
has a high rate of intestinal absorption and all the chelated iron is excreted in the 
urine (Hider et al. 1990). It has less efficient binding profile than 
desferrioxamine, with 3 molecules of deferiprone required to bind one atom of 
iron (Hershko 2005). 
A Meta analysis (Addis et al 1999) of the main deferiprone clinical trials 
conducted between 1989 and 1999 concluded that this drug, at a dose of at least 
75 mg/kg/day, is clinically effective in inducing a negative iron balance and 
reducing the body iron burden in most patients with marked iron overload. 
The most common reported side effects associated with the use of this drug are: 
1- Agranulocytosis (less than a 1% occurrence). 
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2- A decrease in zinc levels. 
3- Mild nausea. 
4- Mild musculoskeletal symptoms (Al Refaie et al. 1992). 
Deferasirox: 
ICL 670 is a new oral iron chelator developed specifically for the treatment of 
chronic iron overload. It is an N- substituted bis- hydroxyphemyl- triazole 
(Hershko 2005). ICL 670 is a tridenate iron (FE +3) chelator, requiring two 
molecules to form a stable complex with each iron atom. The plasma half life of 
ICL 670 (11-19 hours) is suitable for one daily oral dosing (Galanello et al. 
2003). 
Early clinical studies indicate that ICL 670 effectively controls iron levels and 
that a dose of 20 mg/kg/day of it affords equivalent efficacy to DFO 40 
mg/kg/day (Galanello et al. 2003). It must be noted that the first study in humans 
was conducted in Italy (Galanello et al. 2003) in 25 transfusion dependant 
thalassemic patients, receiving single oral doses of ICL 670, ranging from 2.5 to 
80 mg/kg. A short term evaluation of this trial showed that the incidence of 
adverse events was low, even in the group of patients treated with the highest 
dose of drug (80 mg/kg). Its ability to mobilize and promote excretion of tissue 
iron and its good safety profile, as emerged from the first preclinical and clinical 
studies, make this drug the most attractive new iron chelating therapy (Franchis 
2004), in terms of its effectiveness and impact on quality of life. 
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Below is a table summarizing the properties of each of the above mentioned iron 
chelating agents (Hershko 2005): 
Table 1: Properties of iron chelators 
Feature DFO L1 DFX 
Iron binding 
efficiency 
(drug: iron) 
1:1 3:1 2:1 
Iron 
selectivity 
Highly 
selective 
Zinc deficiency Highly 
selective 
Regimen Sc or iv 
infusion 
Oral: 3x/day Oral: 1x/day 
Tolerability 
issues 
Local reaction 
problematic 
Joint problems Skin rashes 
Acceptable 
long term 
safety profile 
Yes Severe 
Neutropenia 
and 
Agranulocytosis 
Unproven 
 
It must be noted that aside from transfusions with iron chelation, there is bone 
marrow transplantation which has proved to be the ultimate treatment regimen 
worldwide as it eliminates the disease and the patient can survive free from it. 
However this management strategy has proven to be expensive and unaffordable 
to many patients. A study by Lucarelli et al have shown that patients who are 
adequately treated with iron chelation, do not have irreversible liver disease and 
have HLA identical related donor have a greater than 90% chance of survival 
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with engraftment of the donor marrow three years after transplantation. However, 
less than 20% of patients with thalassemia meet this criterion (Lucarelli et al. 
1993). 
Efficiency of the various Iron chelators: 
It must be noted that the liver is capable of storing large amount of iron reaching 
about 70% of total body iron stores (about 20 g). Any other extra iron in the body 
is deposited in the liver, or other tissues if the liver is full (Eleftheriou 2003). 
Consequently, iron stored in the liver or other tissues binds to the proteins ferritin 
and haemosiderin (in the same manner as the blood binds to the carrier protein 
transferring). A small amount of ferritin escapes from the liver into the blood 
stream, thus a measure of the level of ferritin in the blood is used to determine 
iron load. 
Normal levels of ferritin in the blood (or serum ferritin) are up to 250µg/l for 
men, and between 10-120 µg/l for women. 1µg of ferritin in the blood is 
considered to correspond to 8 mg of iron in the body‟s stores. Patients with 
thalassemia major with considerably high levels of iron in the body are thus 
expected to have significantly higher ferritin levels (Eleftheriou 2003). 
Although ferritin levels may be a reliable indicator of liver iron stores they are, 
however, less accurate in predicting iron load in other organs, such as the heart, or 
overall body iron load. In addition, other factors such as inflammation, viral or 
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bacterial infections, chronic liver diseases, arthritis and vitamin C deficiency may 
affect serum ferritin levels, indicating higher or lower iron stores than are actually 
present (Eleftheriou 2003; Olivieri et al. 1997).  
Nonetheless, serum ferritin levels are considered the most practical indicator of 
possible iron related complications, as it is the most accessible and inexpensive 
tool for long term monitoring of chelating efficiency (Hershko 2002), compared 
to other procedures such as liver biopsy, computed tomography or magnetic 
susceptibility (SQUID) (Hershko 2002).  
Consequently, some studies have proved that where ferritin levels are consistently 
below 2500µg/l over many years, a patient risk of developing heart complications 
is low (Eleftheriou 2003; Hershko 2002; Oliveiri et al. 1997), these studies have 
estimated a 91% cardiac disease free survival after 15 years compared with only 
less than 20% cardiac disease free survival after the same period otherwise. A 
recent study has also suggested that the combination of liver iron less than 7 mg/g 
dry weight and serum ferritin levels less than 1500µg/l is needed to predict for 
survival free of cardiac disease (Hershko 2002). 
The aim should therefore be to keep serum ferritin levels between 1000-2000 
µg/l, and to check levels at least every three months in order to establish whether 
the patient iron chelating regime needs any adjustments. 
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Compliance: 
According to various studies on Deferoxamine the average compliance rates 
ranged between 77% and 64% (Arboretti et al 2001; Boturao et al 2002; Beratis 
et al 1989; Richardson et al 1993) and the lower rate is to be chosen since 
physicians tend to overestimate compliance rates among their patients (Gabutti 
et al 1996; Delea et al 2007).  
Regarding L1 compliance rates, a study conducted in Italy have showed an 
increased compliance rate by 11.4% from baseline (i.e. from 88% to 98%) thus 
the compliance rate for L1 would be 71% (64%* 1.114) where 54 thalassemia 
patients using the three- times daily oral chelator (L1) and 51 thalassemia 
patients using deferoaxamine were observed for 24 months (Fischer et al 2003). 
The compliance with deferoxamine however has dropped by 4.3% from baseline 
(from 94% to 90%). 
On the other hand, there was no published literature on the compliance rate of 
deferasirox since it‟s a new medication, however, the compliance rate for this 
once daily oral chelator was calculated by Delea et al where they estimated that 
deferasirox would have an even greater compliance rate than L1 as it is a once 
daily oral chelators improving it by 16% (11.4% vs -4.3%) versus deferoxamine. 
Accordingly, compliance with deferasirox was estimated at 74% (64%* 1.16). 
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2.5.  Economic Evaluation of iron chelating management 
Up to our knowledge, there has been no attempt internationally to conduct a full 
economic evaluation of iron chelation therapies and management strategies, rather 
the studies were partial evaluation of the effectiveness of the medications in 
reducing iron overload in the body as has been shown previously. 
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3. Methodology 
The study will be an exploratory, as well as, a descriptive and analytical one. 
Exploratory: since it represents the first attempt to be undertaken to evaluate the 
economic impact of different iron-chelation therapies in the specific context of 
the West Bank. Descriptive: since it will review and describe the characteristics 
of each of the different management strategies in terms of its cost and 
consequences (Efficacy, Effectiveness, and Quality of Life consequences). 
Predictive: since it will examine the cost-effectiveness, cost-utility and cost 
benefit of each of the management strategies to attain conclusions with regard to 
the most medically and economically efficient option to be adopted by the policy-
makers in the area.  
The study relies on cross-sectional data, to be compiled through structured and 
unstructured interviews and questionnaire administration throughout the Master 
Thesis work with both health system providers and patients. 
3.1. Sampling 
The study sample was selected from the thalassemia population in the West Bank 
that are registered in the Thalassemia Patients Friends Association and had 412 
patients registered for 2007. The registered patients were minor, intermediate and 
major thalassemias along with sickle cell patients as they also need blood 
transfusion therefore requiring iron chelation therapies. The Patients were 
  
34 
distributed among various West Bank localities; Ramallah, Jenin, Nablus, 
Hebron, Tulkarem, Qalqilya and Jericho. For our study, minor thalassemic 
patients were eliminated as they do not require iron chelation therapies. A 
proportional stratified sampling was carried out according to locality, sex and age. 
Such a sample method was used to better represent the stratum in the thalassemia 
population, as it is believed that patients in different age groups and different 
localities and gender would be affected differently and possess different 
characters that would affect the results of the study. The unit of analysis was the 
patient her/himself.  
3.2. Theoretical framework 
Three analytical approaches shall be used to assess the costs and consequences 
associated with each of the treatment strategies; 
3.2.1. CEA 
A cost effectiveness analysis will be conducted. Here, the comparison between 
the different medications will be in terms of incremental cost effectiveness ratio 
(ICER), and the effect to be considered is the intermediate outcome of reduced 
iron in the body, which will be measured through serum ferritin levels. As it was 
proved in the literature that reducing iron in the body is a life saver in thalassemia 
patients and contribute to the patients‟ quality of life. This intermediate outcome 
will then be combined with the levels of compliance associated with each 
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medication that have been proved in the literature as such compliance rates vary 
considerably among the three medications thus affecting the effectiveness of 
each. 
In order to compute the ICER, the average costs of both oral chelators will be 
deducted from the average cost of DFO, and this incremental cost will be divided 
by the difference in the effectiveness of the oral chelators and DFO (incremental 
effectiveness). The ICER will be calculated for the three perspectives (MOH, 
patient and society) and the ratio will be compared with an international threshold 
adopted by various health ministries worldwide. 
3.2.2. CUA 
Such analysis will be used to incorporate the „Quality of Life‟ of the patients 
under the different medications, to convert the descriptive quality of life 
information to a utility or a preference-based measure by mapping health states 
from a specific medication onto an established preference weighted classification. 
The QoL scores shall be obtained from Ratip et el questionnaire, where utility has 
to be measured for thalassemia patients in the current status as they are using 
Desferal and to measure the utility when using oral chelators. To perform this, 
quality of life (QoL) score is to be calculated to reflect the preferences of 
thalassemic patients for the various iron chelators.  
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However such questionnaire was developed in an international context and did 
not take into account some countries‟ specificities such as occupation, oppression, 
religion or any other aspect that may affect the QoL of the thalassemia patient. 
Thus, and in order to validate this questionnaire into the Palestinian context, a 
focus group discussion (FGD) was administered to explore and identify any 
specificities that may affect the QoL for thalassemia patients in Palestine. 
In order to compute the ICUR, the average costs of both oral chelators will be 
deducted from the average cost of DFO, and this incremental cost will be divided 
by the difference in the QALYs of the oral chelators and DFO (incremental 
utility), where the latter is calculated by multiplying the QoL scores obtained by 
the average life years a thalassemia patient lives and which averages around 15 
years according to TPFA records and statistics. The ICUR will be calculated for 
the two perspectives (patient and society) and the ratio will be compared with an 
international threshold adopted by various health ministries worldwide. 
The hypothesis to be tested regarding QoL measures would entail the following: 
 Low QoL parameter for thalassemic patients in the Palestinian context. 
 Females are expected to have lower QoL parameter than males. 
 As both education and income levels increase, the QoL parameter would 
be enhanced. 
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A.  Focus Group Discussion: 
FGD is a form of group interview that explicitly uses individual interaction, and 
capitalizes on communication between research participants, in order to generate 
data (Kitzinger et al. 1995). It must be noted that FGD has proved to be 
efficacious in elaborating QoL instruments in various settings and contexts 
(Giacaman et el. 2007). 
One FGD was completed in Ramallah, with 10 participants (7 females and 3 
males), with ages ranging from 7 years to 28 years. 
 The participants covered different localities (Ramallah, Jenin and Tulkarem), as 
well as represented different socio economic backgrounds.  
After representing in front of them the purpose of this FGD, they were asked to 
identify what does QoL means to them in general, then they were presented with 
the determinants of Ratip et al. questionnaire and were asked to identify any new 
determinants that they think determines their QoL as a thalassemia patient in 
Palestine (see appendix 1 for the FGD Script). 
The qualitative data that was gathered was read repeatedly in order to reveal 
certain patterns and themes. The themes were then scheduled in a table and all the 
relative responses were clustered accordingly (Giacaman et el. 2007; Krueger at 
el. 2000). 
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B. QoL score calculation: 
As mentioned above, Ratip et al. has developed a method for measuring the 
clinical and psychosocial burden of thalassemia. As Tefler explained the 
questionnaire process in his paper in 2005 “The clinical instrument includes 
parameters of clinical burden (eg. Transfusion, cardiac problems…etc.) that are 
each scored on the basis of definitions of severity (0= unaffected, 1= mild, 2= 
moderate, 3= severe). Clinical parameters are weighted (eg. Cardiac scoring is 
multiplied by 4, transfusion and Desferal by 3 and growth deformities by 2) and 
can be assessed from patients‟ notes or in collaboration with the clinician in 
charge. 
It is worth mentioning that the weights were decided by 2 physicians Dr. Modell 
and Dr. Wonke (see appendix 4) who worked closely with thalassemia patients. 
This kind of scoring is considered reliable and it could be used in the local 
context as the physicians have the ability to assess these clinical burdens and their 
effects on mortality and weigh them accordingly (Tefler et al, 2005). 
The QoL scores were obtained from various questions that tackled the 
psychosocial aspects in patients‟ lives, these scores were then scaled from 0-3 
were 0 represented normal life and 3 represented severe QoL. The same applied 
for the questions that were inserted from the FGD. The scores of each were then 
added (summed) together to give us a unique QoL score for each patient. This has 
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been done by summing the parameters of QoL defined by Ratip et al 
questionnaire first, and then summing up the parameters obtained by the FGD. 
In addition to that scores have been validated to account for the differences 
between medications, were the clinical burden varied between Desferal and the 
oral medications, in addition to that, certain side effects associated with Desferal 
were not accounted for when calculating the QoL scores for the oral medications. 
Thus we obtained 2 different kinds of QoL scores, one for Desferal and the other 
for the oral medications. 
3.2.3. CBA 
Cost benefit analysis (CBA) is usually favored among other valuation techniques 
as both the cost and the health outcomes take monetary terms.  
To conduct such analysis both the direct and indirect methods are used to measure 
WTP. The WTP will be considered the Benefits from the patients‟ perspective, 
and a net social benefit would be calculated by deducting the Benefits (WTP 
estimated directly and indirectly) from the costs associated with the DFO and oral 
chelators. The hypothesis being tested would be: 
 Patients would be willing to pay the highest amount in order to reduce 
iron levels in their bodies. 
 As income increases patients willingness to pay will also increase. 
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1. Conjoint Analysis:  
In this study we attempt to reflect patients‟ preferences to iron chelation therapies 
and whether a certain attribute of the medication is important relative to other 
attributes (i.e. if a patient would prefer practicing normal life to reducing iron!). 
In addition to that and since deferasirox or L1 (oral chelators) are not yet 
introduced in the Palestinian market we wanted to elicit patients‟ WTP indirectly 
for the oral medications thus acquiring the knowledge if patients would be willing 
to contribute in the cost of their medications since the MOH is refusing to acquire 
oral chelators due to their high costs. 
1.1. How CA is conducted: 
In a general conjoint analysis study respondents would be faced by various 
hypothetical scenarios, such that each involve different levels of attributes that 
have been identified as important and critical to that good or service being 
measured. Accordingly, the respondents are asked to rate, rank or make pair wise 
choices among the various scenarios. 
Rating and ranking methods are largely used in market research, however, many 
researchers prefer to use the pair wise comparison method derived from the 
random utility theory that was developed in transport economics (McFadden 
1973; Ryan 1999).  It is argued that individuals are usually engaged in doing 
choices in their daily basis rather than carrying out ranking or rating methods to 
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choose among various issues. Thus this study will use the choice approach 
depending on that argument. 
The decision making process with the pair wise choices involves a comparison of 
indirect utility functions. Thus in the each scenario the individual is assumed to be 
choosing the alternative that leads to the higher level of utility. Thus a respondent 
will choose intervention B over A if: 
U (Ab, Y, Z
1
) > U (Aa, Y, Z) 
U(.) represents the individuals‟ indirect utility function, Ab are the attributes of 
health care intervention B, Aa are the attributes of health care intervention A, Y is 
the individuals‟ income and Z represents the socioeconomic characteristics of the 
individual that influences their utility. 
However, while the individual knows the nature of their utility function, the 
researcher has no such knowledge and thus this introduces the concept of random 
utility, were an error term is included in the utility function that reflects the 
unobservable factors in the individuals‟ utility function. 
Consequently, the individual will choose B over A if: 
 V (Ab, Y, Z) + εb > V (Aa, Y, Z) + εa. 
                                                          
1
 The attributes include the price of the commodity ( price of the medication) 
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Where V (.) is the measurable component of utility estimated empirically, and εj 
(j= A, B) reflects the unobservable factors in the individuals‟ utility function. 
1.1.1. Establishing attributes: 
In our study 6 attributes were identified as significant predictors of utility for 
using iron chelation therapies and specifically for using infusion chelating therapy 
Deferoxamine or the oral chelators therapies L1 and Deferasirox. The attributes 
were: reducing iron, ease of administration, side effects from using the 
medications, costs per month, the ability to practice life normally and the 
existence of pain when the medications are taken (see table 2). 
1.1.2. Levels of attributes:  
In defining the levels of each attribute, the levels were sought to be realistic and 
that the individual would be willing and able to trade off between them (Ryan, 
1999) 
The cost of the medications represented the maximum and the minimum of 
medication prices in the market in 2007-2008. Table 2 summarizes the attributes 
and the levels of the medications. 
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Table 2: Attributes and levels included in the CA study 
Attribute Level 
Reduces iron Moderately, effectively 
Ease of administration Not easy/ easy 
Side effects Severe/ mild 
Cost per month (NIS) 0, 1000, 1500, 2000, 2500 
Ability to practice life normally No, yes 
Extent of pain while taking the 
medication 
A lot of pain, mild pain, no pain 
 
Each attribute had the following regression code: 
Table 3: Regression codes for attributes and their levels 
Attribute Regression code 
Iron 0      reduce iron moderately 
1      reduce iron effectively 
Admin 0      not easily administered 
1      easily administered 
Comp 0      a lot of complications 
1       few complications 
Life 0       cannot practice life normally 
1      could practice life normally 
Pain 0     a lot of pain 
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1   mild pain 
2   no pain at all 
Cost in 
NIS/ 
month 
0 
500 
1000 
1500 
2000 
2500 
 
1.1.3. Generating the scenarios: 
The attributes and levels presented above give rise to 280 possible scenarios (2^4 
* 3¹ * 5¹). SPSS orthoplan procedure was used to reduce the number of scenarios 
whilst still being able to infer utilities for all possible scenarios (Ryan 1999; SPSS 
ver.15). The technique resulted in an orthogonal main effects design and gave 25 
plus 4 holdout cases. From the 29 scenarios, 50% were selected randomly, giving 
us 18 scenarios, these were then split randomly to two groups each containing 9 
scenarios. From these 9 scenarios, one was randomly selected and then all the 
other 8 were compared to it giving us 8 pair wise choices (see table 4 and Fig.1). 
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Figure One: Example of a pairwise choice experiment in CA questionnaire 
Scenario One: 
Characteristics Medication A Medication B 
Reduces iron Moderately Moderately 
Easily administered Not easy Easy 
Side effects of the 
medication 
Little/ mild A lot/ severe 
The costs per month (NIS) 2,000 1,000 
The ability to have a 
normal life 
Yes Yes 
Pain  during 
administration 
To a large extent No pain 
Which medication do you prefer?                  I prefer Med. A                     I prefer Med. B 
(Tick the box)     
Table 4: Differences between the choices: Medication B- Medication A  
Choice Reduces 
iron 
Easily 
administered 
complications Cost Ability to 
practice 
normal life 
Pain 
Existence 
1 0 1 -1 -1,000 0 2 
2 1 1 -1 -2,000 -1 0 
3¹ 1 0 0 -1,000 0 2 
4 0 0 0 0 -1 2 
5 0 0 0 -2,000 -1 1 
6 0 0 0 -500 -1 1 
7 0 1 -1 500 -1 1 
8 1 0 -1 0 -1 1 
¹ scenarios used to check for internal consistency. 
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1.1.4. Model used for Data Analysis: 
The data obtained from these scenarios is to be analyzed using random effects 
probit model; a Random model was used since the data included a number of 
observations from the same individual (Kennedy 2001) and a probit model was 
used since the dependent variable was binary in form taking 1 and 0 values for 
choosing medication A and B respectively, thus using OLS (Ordinary Least 
Square regression) method would have resulted in heteroscedastic residuals 
yielding inefficient estimates (Ramanathan, 2002).  
The function to be estimated is: 
Δ V = αc + α1 iron+α2 admin+ α3 sideeffects+ α4 cost+ α5 life +α6 pain + е+ u. 
Δ V is the change in utility in moving from medication A to medication B, iron is 
the difference in iron reduced when moving from A to B, admin is the difference 
in the administration, side-effects is the difference between side effects, cost is the 
difference between costs, life is the difference of having a normal life and pain is 
the difference of pain during administration. The unobservable error terms are 
represented by e and u, where e is the error term due to differences amongst 
observations and u is the error term due to differences amongst respondents (Ryan 
and Hughes 1997; Ryan 1999), these error terms are present when using the 
random effects model. 
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The relative size of the coefficients for each attribute is interpreted as the 
propensity to choose a scenario with a specific attribute in it, the higher the 
positive coefficient, the more likely the individual will choose the scenario with 
the attribute in it (Douglas et al 2005). The ratio of the parameters represent the 
MRS with αj/α4 (where j= 1, 2, 3, 4, 5, 6) being an estimate of WTP for levels of 
the individual attributes (Ryan 1999).  
2. Contingent Valuation:    
This paper has attempted to use OE questions sine we have used conjoint analysis 
to elicit WTP for thalassemia patients indirectly for oral chelators and thus our 
aim was to compare this measure with the indirect approach and we used OE 
questions for their ease of administration, and the little time required by the 
respondents to answer such questions so they would not feel boredom answering 
a long questionnaire as shown in the coming section. 
In the questionnaire two open ended questions were asked: 
1. Would you be willing to pay more to receive oral iron chelators? 
2. How much would you be willing to pay per month? 
 A tobit model will be used to analyze the effects of socio economic variables on 
willingness to pay. This model is part of a limited dependent variable models. 
This model was used due to the nature of the dependent variable as it contained 
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many zeros thus we have what is called censored data i.e. the dependent variable 
takes zero but the independent variables are known (Kennedy, 2001).    
 
3.2.4. Cost analysis 
The cost items for thalassemia patients were compiled through various interviews 
with the TPFA, physicians and medical labs. The cost items for the thalassemia 
major patients varies under the three different iron chelators due to differences in 
the medication costs and the requirement of certain examinations that must be 
done more periodically such as the liver function test and the kidney function test 
for the oral iron chelators. It is worth mentioning however that similar annual 
costs between the three medications were eliminated due the interest in 
incremental values between the three medications rather than the gross aggregated 
values for each medication. 
Accordingly, the cost section will be divided to three parts: 
1- Drug costs. 
2- Administration costs. 
3- Examinations needed to verify the effectiveness of the iron chelators in reducing 
body iron and their side effects. 
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The costs were calculated using three age categories since each age require 
different examinations and follow-ups: 
1. Pediatric patients that are under 4 years old, where various heart tests, 
sexual and growth hormones examinations are not performed. 
2. Pediatric patients between the ages of 4 and 12, as they start visiting a 
pediatric cardiologist every six months, and they need to perform the 
growth hormone examinations every year  
3. Patients above 12 years old whom they need the various sexual 
hormones examination every six months. 
In order to calculate the total costs of chelating therapies for the above three 
categories, the perspective of the cost must be specified, thus the paper aimed to 
calculate the costs from the perspective of the MOH, the Patient and the society 
as a whole and in the latter indirect costs shall be added such as the time spent by 
patient or family members of the patient to reach the labs and the working capital 
consumed in the process. 
3.2.5. Questionnaire 
The questionnaire consisted of 6 parts; the first was the patients‟ socio economic 
characteristics section as it consisted of name, sex, age, level of education, level 
of household income, residency and type of disease (intermediate, major and 
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sickle cell). The second and the third part were Ratip et al questionnaire that were 
discussed earlier as he developed a method of measuring the clinical and 
psychosocial burden of thalassemias.  
The fourth part contained the themes that were developed from the focus group 
that was administered on QoL. The questions included asked about social support, 
financial situation, occupation, mechanism of treatment in Palestine and personal 
believes and they were graded on a scale of 1-5 (1= never, 2= sometimes. 3= 
occasionally, 4= a lot, 5= always). 
The fifth part consisted of 8 scenarios (see appendix 2), each scenario consisting 
of 2 choices of medications (A and B) and both having different attributes in 
order to elicit willingness to pay indirectly. 
The last part consisted of a two direct willingness to pay questions; the first asked 
if they are willing to pay more to get an oral medication, and the second asked 
them to explicitly reveal how much they are willing to pay per month. 
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4. Results 
4.1.   Qualitative results 
4.1.1. FGD 
From the FGD it was found that the constituents of Ratip et al. were all agreed 
upon. For example when talking about the treatment mechanism many 
patients revealed their discomfort with the nightly subcutaneous infusions as 
patients expressed: 
“I live a happy life, the needle is the only bad thing that I have to encounter, 
thus the most important thing is to get rid of the needle then I will feel more 
energetic, everything will be available to me and everything in my life will 
change”  
“I wear the needle in the night; I can‟t play in the school” 
Another example on how Ratip et el components were agreed upon was on 
the dimension of  feeling different: 
“I am normal, I only remember that I‟m ill when I go to get blood 
transfusions and the society makes me feel ill” 
“Parents all the time tell me that you are ill, don‟t tire yourself. This is a 
negative thing that affects my life.” 
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Regarding appearance, it was clear that females associated with this 
determinant more strongly than males and was considered the most important 
aspect that affects their QoL: 
“My appearance is the most important thing in my life; I am always on the 
mirror. And thanks God that I don‟t suffer from any facial deformities.” 
“I care a lot for my appearance especially when my face gets yellowish, my 
appearance affects my life and my daily follow ups of my normal life” 
“I don‟t like my face getting darker in color; I love to be like my classmates 
who are white and beautiful” 
However, when discussing the themes of Ratip et al. many other themes 
revealed that seemed specific for the Palestinian patient and that the 
international context did not cover. These were: 
1- Support and Psychological assistance 
2- Mechanism of treatment 
3- Financial situation 
4- Occupation 
5- Lack of confidence in the medical body 
6- Personal believes 
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Regarding the Support and Psychological assistance some patients reflected 
on how lack of support from their community affected them negatively and 
increased their feeling of isolation: 
“People have to support the patient. I feel that I can accomplish anything in 
my life with a strong will” 
“During work I had to get blood transfusion and the manager refused to let 
me go to the hospital. I saw this as a very negative thing that affected my life” 
“Parents play a major role also in the patient‟s life; they must explain to their 
child what to expect in the future so as not to get surprised. They must tell 
him/her about the nature of his/her life, about the iron accumulation and its 
side effects thus psychological preparation is very important” 
“A female nurse (Shahinaz) relieved us from the needles pain” 
“She (the nurse) encourages us to take the treatment; she explains it to us 
too” 
“I want to thank my nurse Shahinaz, she talks to us more than our parents, 
she‟s‟ always telling us that we shouldn‟t care that we are ill. She helps us not 
to feel different” 
Many patients expressed their frustration with the treatment mechanism as 
Ratip et al has showed but what was different in the Palestinian context was 
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not only the frequent visits to the hospitals or blood transfusions, rather many 
patients reported their worries on the blood quality they received and the long 
hours they had to wait for the blood transfusion to complete, also many 
expressed their fears from the side effects that they encounter from needles 
infusions:  
“if they get us new blood I will feel more secure about myself, and I will be 
more encouraged to get Desferal” 
“treatment would be okay for me, but the pain that is associated with taking 
the Desferal and the old blood that we receive is a concern to me, when we 
receive old blood we have to sit for 2 and a half hours getting the transfusion 
since it clots due to this fact. Thus we are getting old blood, iron and above 
all the Desferal needle. I believe that thalassemia patients must receive new 
blood.” 
“When receiving old blood I suffer from fast heartbeats. In addition to that, if 
the blood was old this means that I have to get blood transfusion every week, 
however we are aiming to get high blood concentrations but receiving old 
blood won‟t fulfill this target.” 
“I get bored when I receive blood” 
Also many patients pointed out that the kind of needle that they use increases 
their pain: 
  
55 
„‟ the needle of blood transfusion won‟t enter from the first time and this can 
affect my ability to write thus affecting my studying” 
“I hate treatment I hate doctors and hospitals, everything related to the 
treatment I hate it.” 
From the discussions it was showed that occupation had an effect on patients‟ 
QoL as well as it had effects on the financial status of the patients‟ families 
thus affecting more their QoL: 
“The situation that we live in ( the occupation) affects us negatively. The 
closures affect the person as he/she feels suffocated and that his/her life would 
end” 
“The occupation affects my life, as I get blood transfusions in Ramallah and I 
am from Tulkarem, thus the sudden curfews could prohibit me from reaching 
the hospital, continuously affecting my life” 
“Occupation affected my family resources due to closures; this in turn had 
affected my ability to get treatment” 
“My father is a teacher, and when the political situation deteriorated and they 
went into strike our financial resources were affected and thus I couldn‟t get 
my treatment.” 
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 Interesting views were made concerning the Palestinian medical body as 
some patients expressed their frustrations from their physicians and hospital 
departments and others were impressed by the medical procedures concerning 
thalassemias outside Palestine: 
“ there are many medical treatments that are not found in the West Bank but 
are available in Israel, I once suffered from internal bleeding inside my leg, in 
the West Bank they didn‟t know what to do, but in Israel I made several tests 
and they treated me and stopped the bleeding” 
“In Ramallah there is a big problem, even that we are a strategic location, 
but we don‟t have units, it‟s like we are living in the 90‟s” 
“when I was in Greece, I didn‟t want to return, the needles the use don‟t 
cause pain or irritations, the thalassemia department is fresh and they have 
special features for the kids that allows them to have fun” 
“When I used to go to the pediatrics department no one took care of us” 
From the discussions it was deducted that many patients relied on their 
personal believes to support them through any difficulties, many had built 
defense mechanism either through convincing themselves that they are normal 
and that all will be fine, or by resorting to God and that He is the one who 
could cure them. 
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Thus from the above discussion, each theme was tested for by a set of 
questions in the QoL questionnaire. These questions were placed after Ratip et 
al questions so as not to bias the instrument. The added questions took the 
label of PQOL (see appendix 2), and the following table outlines each theme 
and the corresponding questions for each: 
Table 5: New themes and corresponding questions 
Theme Questions corresponding 
Support and Psychological 
assistance 
PQOL1, PQOL2, PQOL3 
Mechanism of Treatment PQOL4, PQOL16, PQOL 18, PQOL 19 
Financial Situation PQOL5, PQOL6 PQOL17 
Occupation PQOL7, PQOL8, PQOL9, PQOL10 
Lack of confidence in the 
medical body 
PQOL11, PQOL12, PQOL15 
Personal believes PQOL13, PQOL14 
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4.2. Quantitative results 
4.2.1. Cost results 
First: Drug Costs: 
Table 6: Drug costs per patient per year in NIS 
Main Cost Items cost/daily 
use 
Total Cost 
DFO 31.2 11,232 
L1 90 32,400 
DFX 99 35,640 
Source: Ministry of Health 
Table 6 outlines the different iron chelation drug costs, and it can be seen that 
DFO is the cheapest among the 2 other drugs. It is worth mentioning that each 
drug daily cost has been calculated based on the average dosage required by 
the patients, and the total costs represent the average yearly cost per patient. 
Second: Administration costs: 
Table 7: Administration costs per patient per year in NIS 
Main Cost 
Items 
cost/daily 
use 
Frequency of 
Use for 
DFO/year 
DFO total 
cost/year 
Frequency 
of use for 
L1/ year 
L1 total 
cost/year 
Frequency 
of use for 
DFX/year 
DFX 
total 
cost/year 
Butterfly 
needles 
0.714 360 257.04 0 0 0 0 
Plasters 2.04 360 734.4 0 0 0 0 
PUMP 0 0 0 0 0 0 0 
Canola and 
infusion set 
 0 0 0 0 0 0 
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syringe and 
needles 
0.1416 360 50.976 0 0 0 0 
TOTAL   1,042.4  0  0 
          Source: Ministry of Health 
Table 7 summarizes the administration costs of the iron chelation therapies, 
such as needles and plasters etc. And as shown such costs are only true for the 
DFO due to its administration mechanism delineated previously, while the 
oral chelators have no such administration costs.  
Third: Examinations required: 
Table 8: examinations required per patient per year in NIS
2
 
Main Cost 
Items 
cost/daily 
use 
Freqency of 
Use for 
DFO/year 
DFO total 
cost/year 
Frequency of 
use for L1/ 
year 
L1 total 
cost/year 
Frequency 
of use for 
DFX/year 
DFX total 
cost/year 
CBC 3 12 36 12 36 12 36 
Urine 1.31 12 15.72 12 15.72 12 15.72 
Ferritin levels 13.5 2 27 12 162 12 162 
TSI 0.479 2 0.958 12 5.748 12 5.748 
TIBC 1.765 2 3.53 12 21.18 12 21.18 
GPT 0.479 2 0.958 12 5.748 12 5.748 
GOT 0.479 2 0.958 12 5.748 12 5.748 
Billiruben 0.27 2 0.54 12 3.24 12 3.24 
BUN 0.479 2 0.958 12 5.748 12 5.748 
Kreatinine 0.299 2 0.598 12 3.588 12 3.588 
Alk.Phos. 1.617 2 3.234 2 3.234 2 3.234 
                                                          
2
 It should be noted that any similar repeated costs were not included in the cost calculations in each 
perspective. 
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Electrolytes 6.767 2 13.534 2 13.534 2 13.534 
LH 12.75 2 25.5 2 25.5 2 25.5 
FSH 12.75 2 25.5 2 25.5 2 25.5 
E2 10.375 2 20.75 2 20.75 2 20.75 
Testosterone 22.875 2 45.75 2 45.75 2 45.75 
progesterone 17.25 2 34.5 2 34.5 2 34.5 
growth 
hormones* 
60 2 120 2 120 2 120 
GB checkup 20.5 4 82 4 82 4 82 
pediatric and 
hematologists* 
20.5 4 82 4 82 4 82 
pediatric 
cardiologist* 
150 4 600 4 600 4 600 
ECHO* 150 2 300 2 300 2 300 
Cardiologist* 150 2 300 2 300 2 300 
ECG* 100 2 200 2 200 2 200 
MRI* 500 2 1000 2 1000 2 1000 
Eye check* 80 2 160 1 80 1 80 
Hear check* 120 2 240 1 120 1 120 
Source: Ministry of Health 2008,* Examinations that MOH don‟t provide and thus patients pay them directly out 
of their pockets  
Table 8 summarizes the medical examinations costs required by the patients on 
a monthly or yearly basis. Such examinations and their frequencies are what 
each thalassemic patient should have, although Palestinian thalassemic patients 
may not undertake such examinations. The frequency of examinations differ 
from one medication to the other pertaining to the severity of the side effects 
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associated with such medications, especially the oral ones, which is reflected 
by the higher annual costs for these oral chelators when compared to the DFO.  
 Total Costs according to the various perspectives: 
According to the above tables, the direct cost in the perspective of the MOH  
that include the direct costs associated with the drug costs, administration costs 
and examination costs (that are not paid directly by the patient) is as follows: 
 Table 9: treatment cost for one year per patient in NIS from MOH perspective 
Age 
Category 
Total cost 
per year for 
DFO 
Total cost 
per year 
for DFX 
Total cost 
per year 
for L1 
Age<4 
years 
12,310 35,853 32,613 
4=<age<12 12,310 35,853 32,613 
Age>=12 12,310 35,853 32,613 
 
As can be seen from the MOH perspective all age categories share the same level of 
costs for each oral chelators.  
From the patient perspective the total direct costs would include only the out 
of the pocket money spent on any private examination (highlighted by the star 
in schedule 8) along with any transportation costs to reach a laboratory or a 
hospital which is averaged around NIS 7.00/visit for those who take public 
transportations and live in the major cities, however for those who live in rural 
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areas the transportations costs would average around NIS 60/visit
3
. i.e. the 
patient perspective include both direct medical and direct non medical costs. 
Table 10: treatment cost for one year per patient from patient perspective 
Age Category Total cost per year 
for DFO 
Total cost per 
year for DFX 
Total cost per 
year for L1 
Age<4 years 
Rural 
Urban 
 
120 
14 
 
720 
84 
 
720 
84 
4<age<12 
Rural 
Urban 
 
2,720 
2,614 
 
3,120 
2,484 
 
3,120 
2,484 
Age>12 
Rural 
Urban 
 
2,840 
2,734 
 
1,920 
2,604 
 
1,920 
2,604 
 
However, when calculating the societal perspective indirect costs should be 
added that involve time lost and working capital used in the laboratories from 
water, electricity and rents that are realized by the labs that perform the tests 
and neither patients nor MOH pay for them, in addition to adding the costs 
associated with both the MOH and the patient perspectives. The following 
table represents total costs (direct and indirect) that the society encounters: 
                                                          
3
 It is assumed the times required to visit the labs to do the associated examinations would be twice a 
year per DFO patient and 12 times a year per oral chelator patient. 
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Table 11: cost items from societal perspective 
Main Cost 
Items 
cost/daily 
use 
Frequency 
of Use for 
DFO/year 
DFO 
total 
cost/year 
Frequency 
of use for 
L1/ year 
L1 total 
cost/year 
Frequency 
of use for 
DFX/year 
DFX 
total 
cost/year 
DFO 31.2 0             
11,232  
0 0 0 0 
L1 90 0 0 0           
32,400  
0 0 
DFX 99 0 0 0 0 0          
35,640  
Butterfly 
needles 
1.428 360 514.08 0 0 0 0 
Plasters 4.08 360 1468.8 0 0 0 0 
PUMP 0 0 0 0 0 0 0 
Canola 
and 
infusion 
set 
0 0 0 0 0 0 0 
syringe 
and 
needles 
0.2832 360 101.952 0 0 0 0 
CBC 6 12 72 12 72 12 72 
Urine 2.62 12 31.44 12 31.44 12 31.44 
Ferritin 
levels 
27 2 54 12 324 12 324 
TSI 0.958 2 1.916 12 11.496 12 11.496 
TIBC 3.53 2 7.06 12 42.36 12 42.36 
GPT 0.958 2 1.916 12 11.496 12 11.496 
GOT 0.958 2 1.916 12 11.496 12 11.496 
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Billiruben 0.54 2 1.08 12 6.48 12 6.48 
BUN 0.958 2 1.916 12 11.496 12 11.496 
Kreatinine 0.598 2 1.196 12 7.176 12 7.176 
HRS spent 
by 
patients 
2.56 
HRS/visit 990.72 
7925.76 
 12 
245.76 
 12 
245.76 
 
*Source: Nabulsi, 2006 
Table 11 summarizes the cost items included from the societal perspective, 
were it has included direct and non direct medical costs in addition to direct 
non medical costs, mainly represented by the time spent by patients to reach a 
treatment centre, in addition to the time spent in the treatment centre itself. 
This has been differentiated for the 3 medications, where the total cost column 
for each medication indicate the total cost per year per patient for each of the 
needed medications, examinations and direct non medical costs.  
And according to the age categories of patients the societal costs are as 
follows: 
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Table 12: treatment cost for one year per patient from societal perspective 
Age 
Category 
Total cost per year 
for DFO 
Total cost per year 
for DFX 
Total cost per year 
for L1 
< 4 YRS       
rural             21,434     37,032      33,792  
urban             21,328     36,396      32,156  
4< Age<12       
rural             21,834     37,232      33,992  
urban             21,768     36,596      33,356  
>12 YRS       
rural             21,834     37,232      33,992  
urban             21,768    36,596      33,356  
 
4.2.2. Effectiveness results: 
To establish the effectiveness of a patients‟ treatment regime, the amount of 
iron stored in the liver and other body tissues must be estimated. 
Efficiency estimates: 
If we were to calculate the percentage of serum ferritin levels reduced by the 
various medications, then the following simple arithmetic percentage could be 
used: 
Change in serum ferritin level = {(New level- Old level)/ Old level}*100% 
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This would yield a reduction rate of -62.7% for the three medications when 
using the old level as 4,000 µg/l and the new level as 1,500 µg/l. 
As delineated in the literature, the three medications have proved to be 
efficient in reducing iron to the required levels when compliance rates reach 
high levels (Delea et al. 2007) (Hershko 2002), which implies that our 
economic evaluation would be a cost minimization rather than a cost 
effectiveness one. However, since compliance is considered a crucial part in 
reducing iron levels, it could be incorporated in our effectiveness analysis, 
thus varying the results between the medications.  
Effectiveness rate: 
The following table shows the effectiveness of each medication in reducing 
serum ferritin levels, their compliance rates and the calculated effectiveness: 
Table 13: Effectiveness rate calculations 
 DFO DFX L1 
Efficiency measured by amount of serum 
ferritin levels reduced 
62.5% 62.5% 62.5% 
Compliance rate 64% 74% 71% 
Effectiveness rate 40% 46.3% 44.4% 
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It is worth mentioning that when computing the percentage by which each 
medication reduces the iron levels in the body, we took the 4,000 µg/l as the 
highest level of ferritin levels that would be reduced to an average of 1,500 
µg/l.    
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4.2.3. Descriptive results 
To carry out the proportional stratified sampling, 44.5% were selected from 
each locality, males and females represented 55.2% and 44.8% respectively in 
each locality whereas 30% from each locality sample represented the 
population less than 14 years old. Thus the sample size total was 182 patients 
across the various localities. 
It is worth mentioning that when distributing the sample lists on the field 
workers whom were nurses working in the hospitals, it was found that many 
patients were either dead, out of the country, in jail or could not be reached as 
they stopped coming to regular examinations. To tackle this, new sample lists 
had to be made by replacing these patients with others under the same 
categories however the problem reoccurred and thus the nurses were forced to 
interview patients not listed in the sample schedule in order to reach the 
required sample number for each locality regardless of the categories of the 
patients. 
Fifty five percent of the respondents were males and 44.8% were females. The 
respondents were relatively young as 14% were below the age of 6 years and 
49.4% were under the age of 14 years, thus the mean age of the sample was 
15.9 years. Continuously, the age group between 30 years and 63 years were 
only 6.4% of the sample population and this is relevant since most 
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thalassemic patients in Palestine die in an early age (15-20 years) due to iron 
overload.  
Illiteracy constituted 6.4% of the sample population excluding the 6 years and 
below age category (since they did not enroll in school), 44.9% had completed 
elementary level, 25% completed secondary level, followed by 17.3% who 
completed high school. Only 1.9% received a diploma and 4.5% completed 
their bachelors‟ degree. 
The household income per month was relatively low in the thalassemic 
families as 14.4% received a monthly salary between 0-500 NIS and the 
majority of the sample (74.6%) received a salary between 500-2000 NIS, 
whereas only 0.6% received more than 4000 NIS per month. It must be noted 
that the average wage in the West Bank is 1,600 NIS per month.  
The sample contained three forms of diseases of which 63% were major 
thalassemia and 28.2% were intermediate thalassemic patients and only 8.8% 
sickle cell patients. And the patients were distributed as follows: Hebron 
21.6%, Jenin 21.5%, Jericho 3.3%, Nablus 19.9%, Qalqylia 11.1%, Ramallah 
8.3% and Tulkarem 14.4%. 
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4.2.4. QOL results 
Results of Ratip et al. questionnaire for measuring the QoL for thalassemic 
patients are presented in Table 14, which outlines the QoL parameters 
identified by Ratip et al, and the percentage of patients moderately to severely 
affected from thalassemia in each parameter: 
Table 14: descriptive statistics for QoL parameters 
Parameter % of patients scoring moderately to 
severe effect on QoL 
Education 69 
Absenteeism 29 
Sports 48 
Social life 18 
Self image 59 
Feelings of difference 31 
Social integration 56 
Denial 5 
Feeling healthy 34 
Stigmatization 39 
Social isolation 44 
Family adjustments 7 
Anxiety 69 
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Education was the most affected by thalassemia as 69% scored moderate and 
severe effects. Most patients revealed an affected social integration due to 
thalassemia and about near half of the sample had problems with self image 
indicating that more psychological help is needed for the patients in the 
Palestinian community. Also around 70% of the sample suffered from 
Anxiety from the disease. 
However, only 7% of the sample population revealed moderate to severe 
effects on family adjustments from thalassemia and 5% of the patients scored 
moderate to severe effects on the denial parameter. 
            The QoL score: 
The clinical burden and the social aspects measured were added together to 
form the QoL score that ranged from (7-87.5) where the lower limit 
represented patients with a high QoL whereas the upper limit represented the 
worse QoL score, due to the nature of the questionnaire coding, where 0 
referred to unaffected, while 3 represented severely affected. The scores were 
transformed into a 0-100 scale so as 0 would represent the worst QoL score 
and the 100 would indicate a normal person, and the mean result was 64.76 
out of 100.  
However when adding the new questions obtained from the FGD the mean 
score became slightly lower giving a score of 61 out of 100, and indicating a 
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worsening of the patients QoL. This means that the added questions managed 
to capture some aspects that affected the QoL of Palestinian thalassemic 
patients that the international one failed to pinpoint them.  
Following is a table with the newly added themes, and the percentage of 
patients scoring moderate to severe effects on their QoL: 
Table 15: FGD themes and the % of patients‟ scorings 
Themes % of patients scoring moderate to 
severe affects on QoL 
Lack of Support 75% 
Unstable financial situation 66% 
Occupation 51% 
Mechanism of treatment 61% 
Lack of confidence in the 
medical body 
59% 
 
To review how patients responded to the FGD developed questions, 75% 
reported that they did not receive the support they needed; however, 64% 
indicated that they would feel happy if they received such support compared 
to 36% who would feel unhappy if receiving such a support. 
On another hand, the results were mixed on whether thalassemic patients 
thought about their financial status, as 33.1% reported negatively while only 
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16% thought about their financial status frequently, which does contrast with 
the income results that we obtained from the patients indicating their 
unwillingness to reveal their true monthly income. 
30% reported that occupation affected their ability to reach their medical 
centers moderately or severely and continuously, 70% felt anger/ frustration 
due to that fact. In addition to that 54.7% of the sample expressed 
moderate/severe worries of the unavailability of medications and 52% 
indicated that this made them feel insecure about their lives.  
Only 29.8% felt unhappy going to the treatment centre while 70% reported 
that they are okay with that. Accordingly, 43.1% believed in the medical body 
in Palestine as they didn‟t prefer to be thalasemic patients in any other country 
compared to 40% that preferred to be patients outside Palestine. However, 
71% had no trust in their physicians and only 8.2% had complete trust in 
them.  
Sixty seven percent had no trust in the treatment mechanism of Desferal 
compared to 11% who had complete trust and believe in the Desferal, in 
addition to that 34% reported that the Desferal mechanism affected their 
social life moderately or severely compared to 35% who believed that it did 
not have any kind of effect. Almost 96% had not enough financial resources 
to receive the treatment for chelating iron and 88% believed that the treatment 
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mechanism should change compared to 7% who believed it should not change 
at all. 
78% of the patients derived support from their personal believes especially in 
God and that all is in his hands, however 41% felt that their lives had no 
meaning and empty compared to only 19% that reported their content about 
their lives. 
Socioeconomic characteristics and QoL scores: 
When analyzing the effects of the socioeconomic characteristics of the 
patients on their QoL score it was found that the sex of the patient was 
insignificant and did not affect the QoL score. All other indicators; age, 
education, household income and kind of disease have impact on the QoL 
scores as the following table 16 shows: 
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Table 16: QOL affected by various variables 
Coefficient  S.E. 
Constant 53.549* 8.014 
Age 0.643* 0.160 
Sex 0.606** 2.598 
Level of 
education 
-3.242* 1.229 
Household 
monthly 
income 
-3.008* 0.962 
Kind of 
disease 
9.447* 2.321 
R² 0.256  
Adj-R² 0.231  
F-statistic 10.33*  
*significant at the 1% level, **not significant 
The coefficients with a positive sign indicate that as the parameter increases, 
the QoL score increases indicating a bad QoL condition and vice versa
4
.  
Accordingly it was found that as age increased the QoL for patients worsened 
while as patients became more educated their QoL improved 
In addition to that major thalassemia patients had worse QoL scores than 
intermediate patients and this is realistic as intermediate patients have lower 
clinical burden thus lower psychosocial burden. 
                                                          
4
 The regression analysis was done before transforming the scale to the 0-100 range. 
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To test the effects of the socioeconomic factors on the clinical burden of 
thalassemic patients, it was found that again sex was insignificant, while as 
age increased the clinical burden increased, and while the level of education 
increased the clinical burden decreased. This is partially mirrored into the 
QoL sums and could explain the relationship among the socioeconomic 
variables and the QoL scores. 
Table 17: OLS on clinical effects and its relation with various variables 
Coefficient  S.E. 
Constant 5.936*** 4.264 
Age 0.370* 0.104 
Level of 
education 
-1.435** 0.805 
Kind of 
disease 
7.827* 1.526 
R² 0.199  
Adj-R² 0.183  
F-statistic 12.953*  
*significant at the 1% level, **significant at the 10% level, ***not significant 
QoL when using oral iron chelators: 
In order to be able to compare QoL scores between infusion based iron 
chelators and oral chelators, it was attempted to recalculate the QoL score that 
we obtained by adjusting the questions that were relevant to the infusion 
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based iron chelators which were questions PQOL19, PQOL18 and PQOL16 
in the psychosocial section that asked directly whether patients wanted to 
change the current treatment mechanism and  if they were satisfied or not with 
such a mechanism, and questions CL2 and CL7 in the clinical burden section 
that asked about the frequency of taking Desferal and the side effects 
associated with the medication(see appendix 2). The answers were modified 
to reflect the effects of the oral chelators instead thus they were given the 
values of 0 or 1, i.e. reflecting that under oral chelating regimen patients 
would have answered by none or mild effects to the questions discussed 
earlier.   
Accordingly, the QoL score was enhanced as the mean QoL score after being 
transformed into a 0-100 scale was 74 out of 100 compared to 61 out of 100 
indicating a significant improvement in the QoL for the patients when using 
oral iron chelators. 
4.2.5. CA 
From the 183 questionnaires sent 181 completed the conjoint analysis, 
respondents who did not answer scenario 3 correctly since it was the dominant 
one in the set were not included in the analysis since it indicated that they 
either did not understand the technique or did not take the questionnaire 
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seriously and they were 38 respondents thus we were left with 143 
questionnaires to analyze.  
Using a random effects probit model Table 18 presents the main effects 
coefficients: 
Table 18: Random effects probit model results 
Attributes Coefficients Standard 
error 
Iron reduction 0.8944* 0.1314 
Administration 0.51653** 0.164 
Complications 0.9975* 0.180 
Practicing Life 0.6481* 0.0694 
Extent of Pain 0.3099* 0.0428 
Cost -0.0001613* 0.0000479 
rho 0.17159  
Log likelihood -841.662  
n 145  
Chi2 170.71*  
*Significant at 1% level, ** significant at the 2% level 
All attributes were significant at the 1% and 2% levels indicating that all 
attributes that were chosen affect the choice of medications by thalassemia 
patients and all attributes also had their expected signs depending on the 
regression codes, thus if the coefficient had a positive sign it indicates that the 
  
79 
higher is the attribute in B compared to A the more likely patients would 
choose B, whereas if the coefficients had a negative signs it indicates that the 
lower the attribute in B relative to A the more likely patients to choose B. for 
example reducing iron had a positive sign meaning that if medication B 
reduced iron more compared to medication A then patients chose B, the same 
can be said about the easily administered medication and the ability to live 
normal life. However, the attributes pain and complication had also positive 
signs and this was due to the nature of the regression coding as 0 took the 
meaning of severe complications and 1 meant mild complication thus the 
positive sign means that patients chose B if medication B had mild 
complications compared to A and the same applies to pain. The cost attribute 
had a negative sign which means that the less the cost of medication B 
compared to A the more likely that patients chose B. 
It must be noted that we had no dominant attribute; whereby most respondents 
would prefer one attribute over all the other presented attributes, thus 
choosing the medication that had the most preferred attribute. Thus even 
reducing iron was not a dominant attribute as shown in the following table: 
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Table 19: Non dominance for the reducing iron attribute 
 Difference in 
reducing iron 
between medication 
B and A 
Prefer 
Medicine 
B 
Prefer 
Medicine 
A 
Choice1 0 108 73 
Choice2 1 87 94 
Choice3 1 143 38 
Choice4 0 64 116 
Choice5 0 95 84 
Choice6 0 92 89 
Choice7 0 49 131 
Choice8 1 63 117 
 
As can be shown in table 19, even if medication B reduced iron more than 
Medication A, patients did not choose B over A, indicating that the existence 
of other attributes mattered to them. 
Trade off between attributes: 
According to the coefficients sizes, associated complication is the most 
important attribute in choosing the iron chelating medications compared to 
reducing iron, as patients prefer to have mild complications as a side effect 
from using iron chelating therapies compared to severe ones. i.e. they are 
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willing to give up 1.12% (0.9975/0.8944)
5
 of iron reduction to have mild 
rather than severe complications. Patients have shown also their willingness to 
suffer from pain as they consider pain temporary in order to be able to 
practice life normally and be able to easily administer the intake of the 
medication, thus patients are willing to give up 2% (0.6481/0.3099)of feeling 
pain in order to be able practice life normally more and they are willing to 
give up 1.7%(0.51653/0.3099) of feeling pain to have a medication that can 
be easily administered more. The cost attribute was the smallest in size.  
Estimating WTP: 
To estimate the indirect willingness to pay for the attributes, each attribute is 
to be divided by the cost attribute, and table 20 presents the WTP results: 
Table 20: Indirect WTP values 
Attribute Random effects probit 
model WTP (NIS/month) 
Reducing iron 5,544.9 
To be easily administered 3,202.3 
To have less 
complications 
6,184.4 
To practice normal life 4,018 
To reduce pain 1,921.3 
                                                          
5
 The ratio between attributes gives the marginal rate of substitution i.e. it indicates how much patients 
are willing to trade an attribute in order to get more of another attribute. 
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The table indicates that patients were willing to pay NIS 5,544.9/ month to 
reduce iron, whereas they were willing to pay NIS 6,184.4/ month to reduce 
complications. The least amount paid was for reducing pain which amounted 
to NIS 1,921.3/ month. If these were to be summed together, then patients 
were willing to pay NIS 20,870.9/ month to get a medication that reduced 
iron, could be easily administered, had less complications, allowed them to 
practice life normally and had less pain feelings when administered.  
 
4.2.6. CV 
The number of respondents to the open question; of whether they are willing 
to pay extra to get iron chelators were 180 with one missing value, compared 
to 179 to the open bid of how much they were willing to pay per month to get 
an oral chelators with 2 missing values. 56.7% indicated that they were 
willing to pay extra to get an oral chelators compared to 43.3% whom 
answered negatively. The amounts varied considerably as they took the 
amount of 5NIS/ month to 2,000NIS/ month. Around 24.6% were willing to 
pay between 100-200 NIS/month compared to 12.3% that were willing to pay 
between 300-500NIS/month while only 3.3% were willing to pay around 
1,000-2,000 NIS/month. The mean value of the open question was 140.73 
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NIS/month for all respondents and 244NIS/month for respondents willing to 
pay for an oral chelator. 
Table 21: descriptive statistics on direct WTP 
 All 
respondents 
Only respondents 
WTP 
N 179 103 
Mean 
(S.D.) 
140.73 
NIS/month 
(275.1) 
244 NIS/month 
(326.2) 
Minimum-
Maximum 
0 -2,000 5 – 2,000 
 
In order to analyze the effects of socioeconomic variables on willingness to 
pay a tobit model was used which is part of a limited dependent variable 
models. This kind of model was used due to the nature of the dependent 
variable as it contained many zeros thus we have what is called censored data 
i.e. the dependent variable takes zero but the independent variables are known 
(Kennedy, 2001).    
The full model which contained all socioeconomic variables; sex, age, 
education, income and kind of disease was significant with a chi square of 
13.11 (p>0.05), however, both sex and income were insignificant in the 
model.  
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Table 22: tobit model results 
Variables Coefficients Standard 
error 
Significance 
Constant -260.53 151.9 0.088 
Sex -32.462 54.54 0.553 
Age -6.733 3.688 0.07 
Education 63.12 25.676 0.015 
Income 10.988 19.975 0.583 
Kind of 
disease 
113.596 47.83 0.019 
LR chi-square (5) =13.11, p>chi-square=0.0224, loglikelihood=-688.24, pseudo R²=0.0094 
Thus we reduced the model by eliminating the non significant variables and 
the following model was produced: 
Table 23: tobit model results 2 
Variables Coefficients Standard 
error 
Significance 
Constant -246.274 134.202 0.068 
Age -6.87 3.655 0.062 
Education 65.004 25.598 0.012 
Kind of 
disease 
113.18 47.979 0.020 
LR chi-square (3) =12.45, p>chi-square=0.0060, loglikelihood=-688.763, pseudo R²=0.0090 
It can be noticed that the significance improved for all coefficients and from 
the model it can be said that as patients get older they become less WTP for 
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an oral chelator which could be due to the accommodation and the routine that 
the patients have established with the infusion based iron chelating therapy, 
however, it was interesting to note that as patients become more educated, 
they become more WTP for an oral chelators compared to less educated 
patients and major thalassemic patients are more WTP for an oral chelators 
compared to the intermediate thalassemic patients which is logical as major 
patients need more iron chelation than intermediate patients since they get 
more blood transfusions. 
4.2.7. CEA 
MOH Perspective: 
Table 24: CEA using MOH perspective 
OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. 
EFF. ICER 
DFO 12,309.92 0.4    
L1-DFO 32,613.00 0.44 20,303.08 0.04 507,577.1 
DFX-DFO 35,853.00 0.46 23,543.08 0.06 392,384.7 
DFX-L1 35,853.00 0.46 3,240.00 0.02 162,000 
 
Patient Perspective: 
Table 25: CEA using patient perspective for the age category below 4 years 
old 
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OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
120 
14 
 
0.4 
0.4 
   
L1-DFO 
Rural 
Urban  
 
720 
84 
 
0.44 
0.44 
 
600 
70 
 
0.04 
0.04 
 
15,000 
1,750 
DFX- 
DFO 
Rural 
Urban 
 
720 
84 
 
0.46 
0.46 
 
600 
70 
 
0.06 
0.06 
 
10,000 
1,167 
 
Table 26: CEA using patient perspective for age category above 4 years old 
OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
2,720 
2,614 
 
0.4 
0.4 
   
L1-DFO 
Rural 
Urban 
 
3,120 
2,484 
 
0.44 
0.44 
 
400 
(130) 
 
0.04 
0.04 
 
10,000 
(3,250) 
DFX- 
DFO 
Rural  
Urban 
 
 
3,120 
2,484 
 
 
0.46 
0.46 
 
 
400 
(130) 
 
 
0.06 
0.06 
 
 
6,667 
(2,167) 
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Societal Perspective: 
Table 27: CEA using societal perspective for age category of less than 4 years 
old 
OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
21,434 
21,328 
 
0.4 
0.4 
   
L1-DFO 
Rural 
Urban 
 
33,792 
33,156 
 
0.44 
0.44 
 
12,358 
11,828 
 
0.04 
0.04 
 
308,954 
295,704 
DFX-
DFO 
Rural 
Urban 
 
37,032 
36,396 
 
0.46 
0.46 
 
15,598 
15,068 
 
0.06 
0.06 
 
259,969 
251,136 
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Table 28: CEA using societal perspective for patients above 4 years old: 
OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
21,834 
21,728 
 
0.4 
0.4 
   
L1-DFO 
Rural 
Urban 
 
33,992 
33,356 
 
0.44 
0.44 
 
12,158 
11,628 
 
0.04 
0.04 
 
303,954 
290,704 
DFX-
DFO 
Rural 
Urban 
 
37,232 
36,596 
 
0.46 
0.46 
 
15,398 
14,868 
 
0.06 
0.06 
 
256,636 
247,803 
 
From the MOH perspective, the ICER for L1 when compared to DFO was 
NIS 507,577 in order to reduce 1% of the serum ferritin level in the body. 
While the DFX on another hand had an ICER of NIS 392,385 per 1% 
reduction of serum ferritin level when compared to DFO. 
From the patient perspective, the age category below 4 years old had much 
higher costs than the age category above years old, and the patients residing in 
the urban areas had strong dominance for oral chelators over the DFO while 
rural patients ICER ranged from NIS 10,000- NIS 15,000 per percent 
reduction in serum ferritin levels, reflecting mainly the high transportation 
costs incurred by rural patients. The negative sign implies that the cost of both 
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L1 and DFX are lesser than DFO from the patient perspective while their 
efficiency is much more than DFO. 
From the society perspective, there wasn‟t a significant difference between 
age categories, and the DFX remained to be more cost effective than L1  
when compared to DFO, while the rural patients incurred higher costs per 
percentage reduction in serum ferritin levels compared to urban patients. 
4.2.8. CUA 
Patient Perspective: 
Table 29: CUA using patient perspective for age category less than 4 years 
OPTION COST in 
NIS 
EFFECT in 
% 
INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
1,800 
210 
 
9.15 
9.15 
   
Oral 
chelators 
Rural 
Urban 
 
 
10,800 
1,260 
 
 
11.1 
11.1 
 
 
9,000 
1,050 
 
 
1.95 
1.95 
 
 
4,615 
538 
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Table 30: CUA using patient perspective for patients above 4 years old: 
OPTION COST in 
NIS 
EFFECT in  INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
7,800 
6,210 
 
9.15 
9.15 
   
Oral 
chelators 
Rural 
Urban 
 
 
13,800 
4,260 
 
 
11.1 
11.1 
 
 
6,000 
(1,950) 
 
 
1.95 
1.95 
 
 
3,077 
(1,000) 
 
Societal Perspective: 
Table 31: CUA using societal perspective for age category less than 4 years 
OPTION COST in 
NIS 
EFFECT  INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
321,504 
319,914 
 
9.15 
9.15 
   
Oral 
chelators 
Rural 
Urban 
 
 
531,176 
521,636 
 
 
11.1 
11.1 
 
 
209,673 
201,723 
 
 
1.95 
1.95 
 
 
107,524 
103,448 
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Table 32: CUA using societal perspective for patients above 4 years old: 
OPTION COST in 
NIS 
EFFECT   INC.COST INC. Eff. ICER 
DFO 
Rural 
Urban 
 
327,504 
325,914 
 
9.15 
9.15 
   
Oral 
chelators 
Rural 
Urban 
 
 
534,176 
524,636 
 
 
11.1 
11.1 
 
 
206,673 
198,723 
 
 
1.95 
1.95 
 
 
105,986 
101,909 
 
From the patient perspective, and for the age category less than 4 years old, 
the ICUR was 4,615/QALY for rural patients opposed to 538/QALY for 
urban patients. While for the age category of more than 4 years old the ICUR 
was 3,077/QALY for rural patients opposed to strong dominance over DFO 
for urban patients. 
 From the societal perspective, the ICUR yielded ranged from NIS 103,448 – 
NIS 107,524 for each additional QALY for the age category less than 4 years, 
whereas it ranged from NIS 101,909 – NIS 105,986 for the age category over 
4 years old. 
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4.2.9. CBA 
Patient Perspective: 
Table 33: CBA using patient perspective for the oral chelators 
Conjoint Analysis  Contingent Valuation 
Category Cost in 
NIS 
Benefits in 
NIS 
Net Benefits  Benefits 
in NIS 
Net 
Benefits 
Age=<4 
Rural 
Urban 
 
720 
84 
 
250,451 
250,451 
 
249,731 
250,367 
  
2,928 
2,928 
 
2,208 
2,844 
Age>4 
Rural 
Urban 
 
920 
284 
 
250,451 
250,451 
 
249,531 
250,168 
  
2,928 
2,928 
 
2,008 
2,644 
 
When conducting the CBA, there were two outcomes for each category: the 
outcomes obtained from conjoint analysis and the ones obtained from 
contingent valuation. 
Conjoint analysis results: 
This approach had taken the indirect willingness to pay as the outcome to be 
compared with the programmes costs. In addition to that, such an outcome 
was analyzed by either summing up all the 6 attributes introduced earlier or 
by summing the most 2 important attributes to the patient. The net benefit 
using the conjoint analysis approach was positive for all categories and the 
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values yielded were large, indicating the importance of the oral chelators to 
the patients. 
Contingent valuation results: 
This approach used the direct willingness to pay expressed by the patients as 
the benefits; this has also yielded positive net benefits although at lower 
values compared to the conjoint analysis. 
 
5. Discussion 
5.1. CEA 
In the CEA, it was evident that DFX had lower ICER than L1 when compared 
to DFO for all age categories and in all the three perspectives. Whether the 
ICER for reducing 1% of ferritin level in the body is accepted or realistic is 
difficult to determine in the Palestinian context, since the MOH has no league 
tables for such thresholds, nor has the international health ministries any 
threshold values for reducing iron levels in the body. 
However, the calculated ICER for reducing the serum ferritin levels in the 
Palestinian context may be considered too high and unacceptable to the MOH 
or the society, when taking into consideration the GDP levels. GDP /capita in 
the Palestinian territories range around USD 1,177 (NIS 4,708) (PCBS 2007), 
and when using the World Health Organization (WHO) threshold of 
3*GDP/Capita= USD 3,531 (NIS 14,124), the cost of reducing 1% of serum 
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ferritin levels would be considered high and very costly from the MOH and 
society perspective. 
 
One of the major limitations that were faced when conducting CEA was the 
efficiency measure of the iron chelators. It was rigid and more comprehensive 
detailed indicator should be used in order to measure precisely such efficiency 
rate. For example in the Palestinian context, one could use the serum ferritin 
levels of the Palestinian patients for a specific time span, thus more reliable 
and realistic upper levels and lower levels of the serum ferritin would be 
obtained, providing the researcher with an accurate and measurable efficiency 
rate. 
 
5.2. CUA 
5.2.1. QoL 
When comparing Ratip et al. QoL parameters obtained in Palestine within the 
international context, it was found that some parameters were worse than 
other countries while other parameters appeared to compare favorably to other 
countries. 
The education parameter for an example did better in other developed 
countries than Palestine, where the percentage of patients scoring moderate to 
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severe effects on education averaged 40% in US and UK, while in Turkey it 
reached 60%, similar to Palestine.  
However regarding social life, denial and family adjustments Palestine has 
outpaced developed countries, and this could be explained by the strong social 
network that Palestine exhibit compared to other countries.  
 
Regarding the QoL score obtained from Ratip et al. questionnaire, the result 
score indicated that thalassemic patients in Palestine while experiencing 
difficulties in education, social integration and anxiety, they still had a fairly 
good QoL which could be due to the nature of the Palestinian community 
where social networks secure the needed support, and religious believes help 
both patients and families to cope with the disease that they considered 
“qada‟and qadar”. 
 
Considering the socioeconomic characteristic and their effects on QoL score, 
it was surprising that sex was insignificant, as it was expected that females 
would have worse scores on the self image, social integration and social 
isolation indicators but this was proved wrong and that males or females 
experience the same hardships in this kind of disease. 
Regarding the education parameter, it was found that as patients become more 
educated, their QoL was enhanced. This is due to the fact that well educated 
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patients have the ability to better cope with the disease and better understand 
the nature of the disease, thus being able to take more care of themselves than 
others.  
The analysis of QoL parameters and the socioeconomic impact on them 
mirrored the Palestinian context of the disease. Although the results were not 
anticipated regarding the high QoL scores given the factors influencing the 
patients from occupation, low financial capabilities and low treatment quality, 
but again, social networks and support has proved to be the ultimate factor 
contributing to the patients QoL. However, it can be said that these patients 
are in deep and urgent need for a psychological support in addition to 
financial support from their communities. And needless to say that the trust in 
the medical bodies is crucial for the these patients, and thus the Ministry of 
Health need to put more effort, in conjunction with civil institutions, to better 
enhance the medical services given to these patients. 
 
The QoL score has improved significantly when using oral chelators, this is a 
direct result of higher compliance and an anticipated better satisfaction by 
patients if they used oral chelators. However such a score could have been 
more accurately calculated if direct questions regarding oral chelators were 
used, but the QoL questionnaire was designed to measure the current QoL for 
patients, where they used Desferal rather than oral chelators. It would be 
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really interesting to examine directly the real changes in QoL for patients 
when they begin using the oral chelators, which have been in use since 
October 2008. 
The ICUR varied substantially according to the life years survived by the 
patient. If we estimated that the healthy life years gained under oral chelators 
would be the same as DFO which is 15 YRS, then the ICUR would be NIS 
range between NIS 538- NIS 4,615 per QALY for the age under 4 years old 
from the patient perspective, which is considered acceptable using 
international thresholds levels as detailed in table 29 hereunder for UK, 
Australia, Sweden and Germany.  
Table 29: International thresholds values 
 Accepted 
NICE (UK) < NIS 150,000 
PBAC (Australia) <NIS 115,000 
PHARMAC (New Zealand) < NIS 55,000 
SBU, LBF (Sweden) < NIS 175,000 
IQwiG (Germany) < NIS 100,000 
USA <  NIS 200,000 
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It is worth noting however that for the age category above 4 years old, urban 
patients had strong dominance for oral chelators when compared to DFO and 
this mainly reflect the transportation costs that are so low compared to rural 
patients. 
From the societal perspective the ICUR ranged from NIS 101,909 to NIS 
107,524 per QALY, which is also considered acceptable using international 
thresholds. 
 
5.3. CBA 
5.3.1. Conjoint Analysis 
When CA was conducted, our hypothesis was that reducing iron would be the 
major and most important attribute to the patient; however, it came in the 
second place after reducing complication attribute. This was a clear sign that 
Palestinian patients had no clear information about the disease and the causes 
of complication. If they were more informed patients, they should have 
recognized that reducing iron would automatically reduce any severe 
complications that some patients may have experienced.  
Another factor that needed attention was the cost attribute, which was 
significantly low compared to other attributes. This has indicated that patients 
have regarded the costs as unimportant item, and some patients didn‟t even 
consider it when they chose the scenarios as most patients perceived that such 
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costs would be accounted by the MOH rather than the patient her/himself. 
Such factor had distorted the results and affected our interpretation and is 
considered one of the major limitations of the paper. This could have been 
avoided by inserting a statement before the scenarios indicating that the costs 
would be paid directly by the patient. This in turn has caused the large values 
of the WTP when all attributes were divided by the cost attribute.  
The WTP estimated from the conjoint analysis reflect the magnitude and 
importance of each attribute according to the patient, although it is impossible 
for patients to pay such huge amounts monthly for each attribute, such 
analysis is indicative of how important each attribute to the thalassemia 
patients, and that the MOH should not overlook such factors when 
considering any programme for thalassemia patients. 
All in all thalassemia patients were willing to pay NIS 20,871 to get oral 
chelators. 
Of course, the major limitation to such an outcome was the insensitivity and 
non clarity of the questionnaire regarding the cost attribute and that it was 
payable by patients rather than MOH as many patients had implicitly 
hypothesized, distorting the outcomes. 
Another limitation was the length of the questionnaire that may have caused 
some respondents to feel bored and lose their concentration as they reached 
the CA questionnaire. If it were to be done again, a separate questionnaire 
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should be designed for CA and all the proposed scenarios by the SPSS should 
be included in the questionnaire by splitting half of the scenarios and 
distributing them on 2 sets of questionnaires. Such a technique would provide 
more precise outcomes.  
5.3.2. Contingent Valuation 
As discussed earlier, CV was used to elicit willingness to pay directly from 
the patients. 43% were not willing to pay extra to get oral chelators and such 
negative/protest zero answers were expected to be around half the sample. 
The tobit model revealed that income and sex were insignificant regarding 
WTP. The insignificance of sex implied that whether a patient was male or 
female did not affect the patients‟ WTP. On another hand the insignificance of 
income revealed that the household income levels reported by the patients did 
not match the figures they revealed on how much they are willing to pay for 
an oral chelator per month. Some respondents who have identified their 
monthly household income level between NIS 0/month and NIS 1,000/ month 
were willing to pay more than 500 NIS/ month which is not logical since there 
are other expenditure items in the family indicating that patients did not reveal 
their true income levels. 
This is considered from the major limitation of the paper, as the household 
income level question should have not been asked directly, as most 
respondents won‟t reveal such info. This should have been tackled by asking 
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indirect questions such as asking about the monthly household expenditure 
levels. 
 
The cost benefit analysis was conducted from the patient perspective, and the 
net benefit in both methods was positive and large indicating that oral 
chelators were highly beneficial from the patients‟ perspective. However, it is 
worth mentioning, that such outcome was also achieved due to the lower cost 
burdens on the patient as they are all insured and incur only transportation and 
private examinations costs.  
 
6. Recommendations: 
Although the results of economic evaluation that has been done in this paper 
could not be used specifically since they mirror some distortions and 
limitations, however, this paper has succeeded in identifying the major trends 
of the QoL for thalassemia patients in addition to pin pointing the relative 
importance of iron chelation therapy in their lives and its specific attributes. It 
is however, important to have effective awareness campaigns about 
thalassemia in the society in order to further decrease the incidence levels of 
thalassemia. 
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The following recommendations should be viewed with some seriousness from 
the MOH and the community as a whole to better enhance the QoL for 
thalassemia patients: 
1- Oral chelators should be made available to thalassemia patients since it has 
been proved that they could better enhance QoL for patients, in addition to 
better compliance thus reducing side effects from accumulated iron and this 
has been proved by the cost effectiveness of oral chelators over DFO in the 
various perspectives and age categories 
2- Educational sessions should be held for thalassemia patients and their families 
to be better able to handle and manage the disease and thus reducing the side 
effects associated with it. This was evident by the lack of support parameter 
which has severely affected the QoL for patients, in addition to the lack of 
knowledge about the disease by both patients and their families, and this was 
evident in the conjoint analysis exercise and how they weighted the 
importance of the attributes. 
3- More support groups should be formed especially in schools to enhance self 
confidence and social confidence within the patients. 
4- More nurses and medical staff, with enhanced capabilities, should be allocated 
to thalassemia patients, this could also expand to allocating special hospital 
departments for thalassemia or even special clinics distributed in various 
localities to be able to better manage thalassemia patients and assist them in 
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their monthly blood intake, this would enhance the trust in the medical body 
thus improving complicate from the patients side. 
5- Palestinian Labor Laws should be upgraded to include an enforcement law on 
employers to employ thalassemia patients and provide a suitable working 
environment for them.  
6- More resources by the MOH should be allocated to the age category above 4 
years old 
7- Medical centers could be established on the outskirts of each locality rather in 
the centre of the locality, to decrease the financial burden on rural patients, 
and the productivity burden on the society as a whole. 
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8. Appendix: 
Appendix 1: 
Focus Group Discussion: 
Place: Thalassemia Patients Friends Association 
Date: October 31, 2007 
Number: 10 patients (3 males and 7 females) 
Q1. What does QoL means to you? 
Anwar: to live a normal life, I wish that my life could improve and develop; this 
is achievable to me when I take the pill and not the needle. This is because the 
place of the needle stains on my skin and it is very painful to insert the needle. 
Sometimes skin would come off when the needle is inserted. Also when we put 
the belt of the Desferal we cant practice any activities in the school such as sports, 
the muscles of my arm begins to hurt. 
Ahmad: It means that everything others have should be available to me, such as 
medications and treatments. 
Ayat: I feel that my life is normal, I don‟t feel different. 
Lubna: the society perceives us as weak people. 
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Dr Awad: QoL means to me how much I am satisfied with my life, is treatment 
the most important thing in your lives? 
Lubna: what should the patient think of then? Future? No he thinks about 
treatment and about the availability of medication. 
Dr Awad: your thoughts then are as patients only! 
Anwar: we shouldn‟t feel that we are sick. 
Ayat: I am proud of my illness. Only the people around me make me feel that I‟m 
ill. But I have to live a normal life. 
Anwar: I live a happy life; the needle is the only bad thing in it. 
Siham: I wear the needle in the night; I can‟t play in the school. 
Rasha: My motto in life is “no life with despair and no despair with life”. I don‟t 
take things easily, even if I encountered something easy, I know for certain that 
another difficult issue will arise. I lived my childhood in its bitter and difficult 
moments. I admit that I didn‟t live my childhood (didn‟t enjoy it), but every 
moment I lived, I tried to perceive life from a positive perspective and I tried to 
develop my life. Taking the Desferal is suffering, but I don‟t have any alternative, 
so I will continue using it to preserve and keep my life.   
Dr. Awad: if there was an alternative, what would it be? 
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Anwar: the most important thing is to get rid of the needle. 
Ayat: I will be more encouraged to take the medication and will be more 
committed if there was a pill. 
Anwar: I will feel more energetic, everything will be available to me, and 
everything in my life will change. 
Omar: I don‟t feel that I am sick, everything is OK, like any human being. I 
shouldn‟t think I‟m sick always. 
Lubna: To practice life normally, to go out and participate in society, to get rid of 
the thought of illness. 
Anwar: Parents play a major role also in the patient‟s life, they must explain to 
their child what to expect in the future so as not to get surprised. They must tell 
him about the nature of his life, about the iron and its side effects…etc. 
physiological preparation is very important.  
Dr. Awad: do other people affect you QoL? 
Anwar: Friends, they have to be considerate. 
Layali: what are the negative or positive aspects in your life? 
Ahmad: no negative aspects, all is positive. But people have to support the 
patient. I feel that I can accomplish anything in life with a strong will. 
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Rasha: when I was employed in the association, there was a law that all 
organizations must employ 5% from handicapped people. But in reality this is not 
applied, being a patient is an obstacle to me. 
I also worked in the election campaign. In the interview I was very honest and 
told the interviewee that I had thalassemia and they were OK with it and hired me 
from a 4,000 applicant list. However, once and during work, I had to get blood 
transfusion and the manager refused to let me go to the hospital. I saw this as a 
very negative thing that affected my life. 
Ayat: The situation that we live in (the occupation) affects us negatively. The 
closures affect the person as he feels suffocated and that his life would end. For 
me I don‟t feel this, as in our country we have no closures.  
Anwar: the occupation does affect my life, as I get blood transfusions in 
Ramallah and I am from Tulkarem, thus the sudden curfews could prohibit me 
from reaching the hospital, continuously affecting my life. 
Rasha: the negative thing is that we can‟t enter Jerusalem; we must have a 
permit. 
Dr. Awad: Is there any medical treatments that are not found in the WB but 
are found in Israel? 
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Rasha: Many actually, I once suffered from internal bleeding inside my leg, in 
the WB they didn‟t know what to do! But in Israel I made several tests and they 
treated me and stopped the bleeding. 
Anwar: I also get these bleedings occasionally, but I didn‟t know why! The 
doctors said to me not to play a lot. 
Ahamd: the negative thing in my life is that I cannot travel because I need 
constant blood transfusions. 
Q2. Do you think any of the following determinants affect you QoL? 
A- Feeling different: 
Anwar: I don‟t feel that I am different. I don‟t care. 
Ayat: I‟m normal. I only remember that I‟m ill only when I go to get blood 
transfusions, and the society also makes me feel ill. 
Anwar: I want to thank my nurse Shahinaz, she talks to us more than our parents, 
she‟s always telling us that we shouldn‟t care that we are ill. She helps us not to 
feel different. 
Dr. Awad: Is feeling different something negative? 
Anwar: I don‟t know, I just don‟t care. I am a normal person; the only difference 
is that I get blood transfusion. 
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Lubna: If parents gave us the support to fight this, it would have been something 
normal. But parents all the time tell me that you are ill, don‟t tire yourself. This is 
a negative thing that affects my life. 
Ayat: My teacher also had a great role in my life, as he supports me and talks to 
me when I get tired, he tells me that everything is normal. For me I don‟t care. 
Omar: no, it does not affect me. 
Ahamd: relax 
Ahamd T.: I don‟t feel anything. 
B- Appearance: 
Anawr: my appearance is the most important thing in my life, I am always on the 
mirror. People who suffer from deformities of the face bones may affect them 
negatively, for me thanks God, I don‟t suffer from this. The most important thing 
in my appearance is my face. 
Rasha: I care a lot  for my appearance especially when my face gets yellowish 
,also my parents bother me in that matter ,but my appearance affects my life ,and 
my daily follow up of my normal life . 
Ayat: I don‟t like my face getting darker ,because when iron increases in my 
body ,the darkness of my skin increases ,I love to be like my classmates who are 
white and beautiful. 
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Ahmad : I don‟t care about my appearance as long as I‟m with the company of 
my friends ,if somebody gave me the weird look ,I won‟t go out ,if not ,then 
everything is Fine. 
Omar: appearance is normal, it is not as important to me as females. 
Anwaar : males are different than females ,they don‟t care about their appearance 
as much . 
C- Treatment: 
Anwaar : treatment is normal only the pain that comes from the Desferal or 
associated with its use, and the old blood that we receive is a concern to me. 
When we receive old blood we have to sit for 2 and half hours getting the 
transfusion since it clots due to this fact. So we are getting old blood, iron and 
above all the Desferal needle, however  treatment has only one negative side-
effect to us stressing on the needle. Thus the negative aspect of the treatment to 
me is the needle of the Desferal and the old blood. I believe that all thalassemia 
patients must receive new blood. 
Dr Awad: if treatment changed would this increase your lives satisfaction? 
Anwaar: if they get us new blood, I‟ll feel more secure about myself, and I‟ll be 
encouraged to get Desferal . 
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Ayat : from the side effect I get from the old blood is fast heartbeats, and if the 
blood was old this means that I have to get blood transfusion every week .for us 
we are aiming to get high blood concentrations however receiving old blood wont 
fulfill that target .also my adherence to Desferal is low . 
Ahmad: treatment is not encouraging; if there are people who encourage or care 
for me I will undergo the treatment. 
Anwar asks Ahmad, when you get blood transfusion how do you feel ? 
Ahmad : bored . 
Rasha : in Ramallah there is a big problem ,even that we are a strategic location 
,but we don‟t have Units it‟s like we are living in the 90‟s  we have absent rights 
.I agree that you feel bored(you sit for 3 hours for the transfusion) and you put the 
Desferal daily at night ,however not all our patients love to read ,as some love to 
jog or watch Television ,there is pressure . 
Ayaat: the needle of the blood transfusion won‟t enter from the first time and this 
can affect my ability to write thus affecting studying. 
Ahmad (2): when I get blood transfusion I feel pain, it hurts my arm, I don‟t feel 
happy going to the hospital (I go to the hospital alone). 
Mahdiya: treatment is a large part of my life, I don‟t receive Desferal because 
I‟m allergic to it and this affects my health (but it became natural to me). 
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Lubna : I don‟t also put Desferal ,I drink tea , with food as it breaks the iron , I 
used to feel very tired when I put Desferal ,and now thanks to God everything is 
normal . 
Ayat: when I put the Desferal it hurts where the needle is placed, there are people 
who feel ashamed when they put that machine in front of people, I don‟t. I want 
to be a nurse. 
Anwaar: everything that we said refers to the nurse, when we were young we 
were attended by several nurses. 
Lubna: Shahinaz relieved us from the needles pain. 
Anwar: she encourages us to take the treatment, and she explains it to us. 
Ahmad : if I was stressed I don‟t get blood ,even if this would affect my life ,I 
don‟t feel like receiving blood, this could be due to personal reasons or others . 
Ayat: when I have my mid-terms I delay the blood transfusions date, I want also 
to add that when we used to go to the pediatrics department no one took care of 
us, and we faced problems, now at the Thalassemia department they care for us, 
at the Department people provide us with guidance and all the thanks for 
Shahinaz. 
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Omar :everything is normal ,treatment is not only blood and Desferal ,it is also 
spiritual ,we need a strong will ,the will that I don‟t keep thinking I‟m sick ,and 
not to feel that I cant get married because I have Thalassemia and such stuff . 
Anwaar: the thing he is talking about goes back to feeling different ,if the girl 
wants to get married ,she will say I have Thalassemia and I don‟t want to get 
married ,this is feeling different ,and I don‟t want to think like this . 
Ayat: I want to add that any bad thing that I encounter I don‟t love for others to 
encounter or face. 
Rahsa: also food is included within treatment, I shouldn‟t eat food that contains 
Iron . 
Siham: I feel normal, bored, the blood transfusion is so slow. 
Anwaar: the food ! all the food has iron (I only eat milk dairies and tea).The Cola 
,I love Cola I will die for it ,sometimes to drink it I pour in it tea but I‟ve been 
avoiding it for four months . 
Rasha: we don‟t drink Cola due to Osteoporosis. 
Ahmad:I hate treatment I hate doctors and hospitals ,everything related to the 
treatment I hate it ,I feel it is not good for me ,treatment doesn‟t extend life 
,treatment is something routine ,treatment doesn‟t improve my life . 
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Anwaar: you aren‟t supposed to say these things, you will have spleen 
enlargement, Osteoporosis… etc leading to your death . 
Ahmad: if they developed the treatment a person would think about the future 
more .I don‟t like treatment it‟s boring. 
Siham :I don‟t like Desferal because it takes time and we have school so we have 
to remove it at 7:00 a.m. even if it was not completed ,I don‟t get upset but my 
mother get worried . 
Ayat : I want you to know that when our weight increases we have to increase the 
Desferal thus the burn of the skin increases . 
Rasha: we can evaluate how effective is the desferal through urine and the color 
of the face. 
Layali: do you feel happy when Desferal is effective? 
Anwar: absolutely every person wants the best for themselves. 
Ahmad: no  
Khitam: from the face appearance a person reveals if he/she has used Desferal or 
not. 
D- Sexual development. 
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Lubna: I got affected when my period was late, it came to me when I was 
sixteen, then everything was normal. 
Rasha: everybody who sees me knows how Rasha evolved ,I grew up fast, it 
wasn‟t something easy. I used to talk to my mother and sister and ask my sister 
why is your weight more than mine, and this is this simplest matter that crosses 
the mind of a girl . 
I used also to go and ask my friends why am I like this, why am I different!! 
My father convinced me that what I have other don‟t posses .my parents helped 
me a lot. parents play a major role. 
Anwaar: I don‟t think about this subject. 
Siham: I don‟t have fears ,but I think about it a lot . 
Lubna: before, I used to think why my classmates had their period and I didn‟t, it 
worried me. 
Ahmad: I have a twin brother my brother works in the police force, he is as tall as 
the door, and he has all the male characteristics, I wish I can be like him. 
Anwaar: because he is your twin you feel different more and more. 
Omar: I feel normal; I‟m like all the other guys. 
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Siham: I heard that if I don‟t get the period, I wouldn‟t have children, is that 
correct? 
E- Side-effects. 
Ayat: when I get blood infusion I get fast heartbeats thus I must return to the 
hospital, it hurts me deeply that I have to return to the hospital   
Rasha: I used to develop allergies and used to return regularly to the hospital 
when I get blood transfusions, my relative who lives abroad is a professor and 
was visiting us when this occurred to me, and she examined me and subscribed to 
me a new medication, now I can‟t take blood transfusion unless I take this 
medication, the problem is that this medicine makes me sleepy and has affected 
my life a great deal. 
Anwaar : I get headaches . 
Ayaat: the only thing is that when I get the blood transfusion I become normal, 
this gives me hope, to continue with the medication so that my blood would 
become more concentrated. 
Anwar: the treatment has negative and positive aspects, for me I suffer from high 
pressure, fever and my joints occasionally hurt me . 
Ahmad: I don‟t have any side-effects only headaches. 
Ahmad 2: headaches and pain in my legs, and that makes me upset. 
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F- Future uncertainties. 
Ayat: I have ambitions, my classmates who are normal don‟t have plans, for me I 
have plans and goals for my future. I want to be a nurse. 
Lubna: I don‟t think about the future and it does affect my life, I want to work 
because it stresses me to stay at home. 
Ahmad: to me the future is a surprise, I don‟t expect anything. 
Lubna: not everyone gets what they plan. 
Rasha: off course I have ambitions. 
Siham: I think of Gaza all my relatives are there, I don‟t have anybody here all 
our relatives are in Gaza, I want to return to Gaza. 
Anwar: when I was young the days were good ,I used to run and play in the 
streets, when I grew up I began thinking about the advises my mother gave me 
,by the way I‟m a Television host ,and you know kids when I go back to school 
they all ask me about it ! and I answer them tomorrow you will see ,when the girls 
and the principle ask me what do you want to study I respond ,journalism ,and 
they answer back alas ,once a girl made fun of me and the principle told me that 
she is jealous ,I see myself as a television host and a journalist ,I am certain of my 
future inshala .  
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Omar: I‟m like the rest of the world, off course every person thinks of the future, 
fate is in the hands of god, we do what we have to do. 
Ahmad : sometimes I think about the future when I‟m alone .when I‟m taking the 
medication I don‟t think about the future ,I‟m not sure about the future . 
Ahmad 2: I want to be a doctor. 
G- Family stability. 
Ahmad: there are some parents who care, and others who don‟t, and this affects 
me; when they care I am encouraged, if not there will be negligence in every 
aspect. 
Anwaar : the family shouldn‟t distinguish between the patient and other siblings 
.they have to continue doing their activities. when the patient is aware he can go 
alone to the hospital ,without the need of anyone‟s help. My family is a normal 
one. 
Ayat : our parents try to engage us in the society that‟s why they let us go alone 
to the hospital ,my parents put me in one hand and all the other family members 
are on the other hand ,I am considered a major part I occupy their thought a lot 
.my mother sacrifices here time by taking care of me and this makes me feel 
happy . I tell her not to stay with me and try to ease things on her, but I love her 
presence around me . 
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Lubna: off course my parents are beside me this makes me feel happy ,when I 
say Ahh my father becomes confused with thoughts and escorts me to the hospital 
,I am happy . 
Ayat : I feel my mother is more gentle with me than my father ,this makes me 
feel happy ,she abandons all here work to be with me . 
Rasha: I am the concern of my family, my mother taught me to carry the 
responsibility ten years ago, I had benefited from my parents especially from my 
father, this made me feel happy but deep inside I felt that I consumed their time,if 
my mother was with me during my sickness I used to feel I‟m a burden on her, as 
she used to spend enormous hours with me ,however this did not affect my family 
stability and our activities continued normally . I have lots of friends. at a certain 
point my grandfather and father became sick, thus tasks were delegated to other 
under this roof, it was a very difficult time, but I stayed the main and essential 
task among all. 
Shahinaz: usually children above the age of 12 arrive alone to the hospital, other 
than that they come accompanied by their mothers. 
Ayat :my parents have to come with me because I am a female and there are 
several army checkpoints ,and if I got sick in the hospital they would stay with me 
.once they denied me access on the checkpoint ,I started crying ,really got 
devastated this led me to the E.R. 
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Omar : no everything is normal I go alone to the hospital ,off course my mother 
sacrifices here time ,however parents shouldn‟t give us advices left and right ,this 
makes me more sick . 
Ahmad: everything is normal back home, I go to the hospital alone, when I was a 
child my parents used to escort me. I used to feel happy when my mother used to 
come with me. 
Ahmad 2: I go alone to the hospital, I love going alone. 
Q3. Determinants of QoL: 
A- Age: 
Anwar: I take everything normal, when the person is more aware he will know 
everything about himself, and now I am more aware about my disease. Children 
remain children, sometimes I get afraid, However, when I was a little girl I used 
to play and run and drink Cola, I wasn‟t aware of my disease. 
Lubna: when I used to take Desferal and blood I used to feel better, before when 
I was little, no I didn‟t feel better or okay with that. I have a brother and a sister 
who died from that disease. I was devastated after their death. And Desferal 
destroyed me more, I don‟t know why! 
Ayat: whoever sees me doesn‟t think I am a Tawjihi student. Things are different 
now as I became aware , before, I didn‟t like to go to the hospital, but when I 
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became a grown up, it became something normal, routine, I can‟t abandon it, it 
makes me think about the future, makes me feel independent. 
Omar: when I was a small boy I was short, but when I took the hormones I 
became taller. 
Ahmad: I love to return to my childhood, because as I grow up I become more 
aware of my life and I know things. But when I was little things didn‟t matter to 
me. 
B- Sex: 
Ayat: appearance affects me, I love being a Palestinian, because everybody is 
considerate in our case. 
Because I am a female my parents don‟t allow me to go out, that‟s why I love 
school more than vacations. 
Anwar: For me everything is normal, I have my freedom now more than before. 
Lubna: yap it does affect me, when I want to go out they don‟t allow me, I 
always feel suffocated. 
Ahmad: In the night I want to go out but my parents begin to advise me that I 
shouldn‟t be late, and that I shouldn‟t go too far, I usually put the Desferal and go 
out. 
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Omar: for me its normal, it does not affect me. 
Anwar: males are different than females, females are more restrained. 
Ayat: males and females nowadays are the same; they all love to be cool and 
trendy. 
C- Occupation: 
Ayat: occupation affected my family resources due to closures; this in turn had 
affected my ability to get treatment. 
Anwar: my father is a teacher, and when the political situation deteriorated and 
they went into strike our financial resources were affected and thus I couldn‟t get 
my treatment. 
Q4. What do you think also determines your QoL? 
Rasha: Having specialist physicians and having periodic checkups affect my life 
greatly. 
Anwar and Ayat: The pre marital checkups affect our lives deeply, and also 
having a better department that could cater to our needs. 
Q5. After your review of the Questionnaire do you think it needs any 
amendments or addition? Is it easy? 
All: It is easy to read and we can understand. 
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 :2 xidneppA
  .محضة و لٌست لأي غرض أخر بحثٌةجمٌع المعلومات فً هذه الاستمارة هً لأغراض 
 
تهدف الى قٌاس جودة حٌاة مرضى الثلاسٌمٌا فً الضفة  وهذه الاستمارة هً عبارة عن تتمة لرسالة ماجستٌر فً الاقتصاد 
  : الغربٌة، فً البداٌة أود أن أسئلك بعض الاسئلة العامة عن نفسك
 1.DI الاسم 
  ذكر .1 
  أنثى. 2
  2.DI الجنس
 3.DI   عمرك بالسنوات الكاملة؟ ما هو 
 
 
 
 
  أمً .1
  ابتدائً.2
  اعدادي.3
  ثانوي.4
  م متوسطودبل.5
  بكالورٌس .6
  ماجستٌر .7
 4.DI  أعلى شهادة أتممتها بنجاح؟ما هً 
  005-0. 1 
 0001-005. 2
 0051-0001. 3
 0002-0051. 4
 0052-0002. 5
 0003-0052. 6
 0053-0003. 7
 0004-0053. 8
  0004أكثر من . 9
 5.DI  ؟)بالشٌقل(ما هو معدل الدخل الشهري للأسرة 
 6.DI  ؟)المدٌنة/ القرٌة (أٌن تسكن  
  ثلاسٌمٌا متوسطة. 1 
  ثلاسٌمٌا عظمى. 2
  فقر الدم المنجلً. 3
 7.DI ما هو نوع مرضك؟
 
 
 
أن تجٌب عن جمٌع الاسئلة و اذا كنت غٌر متأكد من الجواب الرجاء اختٌار الجواب الاسئلة التالٌة تتعلق بوضعك الصحً، الرجاء 
  .الأكثر تلاؤما
 
 
 
 
  أحتاجلا  .0
  فً السنة مرتٌنمرة أو  .1
  ثلاث أو أربع مرات فً السنة .2
  أكثر من أربع مرات فً السنة .3
 1.LC  تحتاج الى نقل دم؟كم مرة 
  أتلقىلا  .0 
  فً الاسبوع ةمن مر أقلمرة أو . 1
  فً الاسبوع مرات 3 أو مرتٌن .2
  فً الاسبوعمرات  ثلاثأكثر من  .3
 
 2.LC  ؟رالكم مرة تتلقى الدٌسؾ
 
 
 
  لا .0
  أقل من عام لمدة نعم، مرة واحدة .1
بٌن سنة نعم، مرتٌن أو مرة دامت ما  .2
 وسنتان
أو مرة واحدة و دامت / مرتٌنأكثر من نعم،  .3
 3.LC  ؟ظهرت لدٌك تقرحات فً الأرجلهل 
  
 231
  أكثر من سنتٌن 
 
  لا .0 
  أحٌانا مع أعراض وألمنعم،  .1
  نعم، مع الام متكررة .2
  إستئصال المرارةنعم، تم  .3
 
 4.LC  ؟حصوة فً المرارةعانٌت من هل 
 
 
 
لا ٌوجد تضخم أو تضخم بدون تأثٌر على  .0
 الدم
  متضخم لكن تأثٌره بسٌط على الدمنعم،  .1
لى الدم لكن ضخم مع تأثٌر واضح عمت نعم، . 2
  الطحال ب إستئصالللٌس بالقدر الذي ٌتط
  إستئصال الطحال نعم، تم. 3
 
 
 5.LC  ؟هل ٌوجد لدٌك تضخم فً الطحال
 
 
  
 
  لا .0
  رؤٌته بالتدقٌق ، ٌمكن بسٌطنعم، تشوه  .1
  واضح لكن لٌس شدٌد ،متوسطنعم، تشوه  .2
  تجمٌل شدٌد أو ٌحتاج لعملٌاتنعم، تشوه  .3
 
 
 
 
  ؟هل لدٌك تشوهات فً الوجه
 
 
 
 6.LC
 
 
  لا  .0 
، لا تؤثر على نشاطاتك أحٌانا وطفٌفهنعم،  .1
 الٌومٌة
، تؤثر على نشاطاتك كثٌرة ومتوسطةنعم،  .2
 بشكل ملحوظ
، تؤثر على نشاطاتك مستمرة وشدٌدةنعم،  .3
 بشكل كبٌر
 
 7.LC  ؟هل لدٌك ألام فً العظام و المفاصل
  لا .0 
  نعم، كسر واحد .1
  إثنٌننعم، كسرٌن  .2
  كسور ثلاثة نعم، . 3
 
 8.LC  ؟كسورعانٌت من هل 
  لا .0 
  وطفٌؾفً أذن واحدة  نعم،. 1
أذن واحدة وطفٌؾ، أو  نعم، فً الأذنٌن .2
 وشدٌد
  وشدٌد نعم، فً الأذنٌن .3
 
 9.LC  ؟هل لدٌك مشكلة فً السمع
  لا .0 
  من باقً الناسلكن أكثر  بتكرارلٌست نعم،  .1
المستشفى  تضطر لدخولمتكررة، أونعم،  .2
  لتهاباتالا بسببأحٌانا 
 بسببالمستشفى كثٌرا  نعم، تضطر لدخول .3
  لتهاباتالا
 
 01.LC  التهابات؟/ عانٌت من عدوىهل 
  لا .0 
  الطول أقل من المعدل قلٌلانعم،  .1
 11.LC  ؟هل لدٌك مشاكل فً النمو
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  الطول أقل من المعدل بالثلثنعم،  .2
  من المعدل بأكثر من الثلثالطول أقل نعم،  .3
 
31 عاما انتقل الى سؤال 31اذا كنت أصغر من 
 
  لا  .0 
عدم خصوبة لعام، أو تأخر فً البلوغ نعم،  .1
 لعام
عدم خصوبة لعام أو إثنٌن، أو تأخر فً نعم،  .2
عدم ( البلوغ لأكثر من عام، أو عجز بسٌط
  )بالقدرة على الانجا
عدم خصوبة لأكثر من عامٌن، أو  نعم، . 3
 عدم بلوغ، أو عجز
 
  ؟جنسًال تأخر فً التطورهل تعانً من 
 
 21.LC
  لا  .0 
تحتاج الى الراحة : ٌوجد ضعؾ بسٌط نعم،. 1
بشكل متواصل، تستطٌع المشً أكثر من كٌلو و 
  درجة 02تستطٌع صعود 
تستطٌع : تأثرت الحركة بشكل واضح نعم،. 2
شً بٌن نصؾ الكٌلو و الكٌلو أو صعود بٌن الم
  درجة 51 – 01
 تستطٌع السٌر فقط لأقل من نصؾ مٌلنعم،  .3
  درجات 01أو صعود أقل من 
 
 
 
 31.LC  و التنقل؟ هل لدٌك مشكلة فً الحركة
  و لا مرة .0 
  واحدة مرة .1
  مرتان .2
  ثلاث مرات .3
 
 فً السنة الواحدةما هو معدل دخولك للمستشفى 
  ؟ؼٌر حالات نقل الدمل
 41.LC
لم ٌتأثر لا، . 0 
أو  B الوبائً إلتهاب الكبدنعم، أعانً من . 1
 C
 ahpla( نعم، أحتاج الى أخذ دواء .2
)  norefretni
تشمع كبد أو ورم فً الكبد نعم، لدي  .3
 
 51.LC  ؟هل لدٌك مشكلة فً الكبد
  لا  .0 
  تتبع حمٌة ؼذائٌةنعم،  .1
  ؼذائٌة ب وتتبع حمٌةتأخذ حبونعم،  .2
تأخذ إبر انسولٌن وتتبع حمٌة أو لدٌك  نعم،. 3
بسبب  أو العٌنٌن مشاكل فً المسالك البولٌة
 السكري
 
 61.LC  ؟هل لدٌك سكري
  لم ٌتأثر لا،. 0 
، و لا تؤثر على مشاكل طفٌفةنعم،  .1
  النشاطات الٌومٌة
أعراض فً القلب تحتاج إلى  نعم، ٌوجد. 2
بشكل بسٌط على النشاطات تؤثر  و أدوٌة
 الٌومٌة
 71.LC  ؟هل لدٌك مشاكل فً القلب
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فشل فً القلب ٌحتاج لعلاج نعم، لدٌك  .3
  و تضطر لملازمة البٌت مستمر بالأدوٌة
 
  لا .0 
الدرقٌة أو  تأخذ حبوب لعلاج الؽدةنعم، . 1
 الفوق درقٌة
الدرقٌة و الفوق  تأخذ أدوٌة لعلاج الؽدةنعم،  .2
 درقٌة
تم إدخالك المستشفى بسبب نقص  م،نع. 3
  تشنجات تتطلب أدوٌة فً الورٌد و وجود الكلس
 
 81.LC هل لدٌك مشكلة فً الؽدة الدرقٌة أو الفوق درقٌة؟
 
 
 
 
 
 
 
 
 
 
 
: الأسئلة التالٌة تخص جوانب حٌاتك الٌومٌة
متدنً  .1 كان تقدٌرك فً المدرسة؟/ما هو A.1.TR
متوسط  .2
متفوق  .3
 
تعتقد أنه كان بامكانك ان تحصل على تقدٌر  هل B.1.TR
 أفضل لو لم تكن تعانً من مرض الثلاسٌمٌا؟
نعم . 1
لا  .2
 
الى الؽٌاب عن بعض  اضطررت/هل تضطر 2.TR
 الأٌام الدراسٌة؟
   ، ابدالا .1
ٌوم أو أقل فً الشهر  نعم،  .2
أسبوع أو أقل فً الشهر       نعم،  .3
 الشهر    أكثر من أسبوع فً نعم،  .4
 
 لا، ابدا .1 هل تؤثر الثلاسٌمٌا على نشاطاتك الرٌاضٌة؟ A.3.TR
قلٌلا نعم،  .2
كثٌرا نعم،  .3
 
لو لم ٌكن  أفضل من ذلكتحقٌق  بامكانكهل كان  B.3.TR
 لدٌك ثلاسٌمٌا؟
نعم  .1
لا  .2
 
 الإجتماعٌة؟مشاركتك هل تؤثر الثلاسٌما على  4.TR
 ..).الجامع/ الذهاب للنوادي(
 
أبدا لا،  .1
قلٌلا نعم،  .2
 كثٌرانعم،  .3
 
 
 هل تؤثر الثلاسٌمٌا على علاقتك بأصدقائك؟ 5.TR
 
أبدا لا،  .1
قلٌلا نعم،  .2
كثٌرا نعم،  .3
 
 ؟مصدر قلق لدٌك الثلاسٌمٌا مرضهل  6.TR
 
أبدا لا،  .1
 قلٌلانعم،  .2
نعم، أحٌانا . 3
 نعم، كثٌرا. 4
 نعم، دائما. 5
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 قلق لدٌك؟/ هو أكبر تخوؾ  ما 7.TR
 
 
 آمالك للمستقبل؟ أهم ما هً 8.TR
 
طبٌعً  /أن أكون سلٌم .1
  
أن أتمكن من الإنجاب  .2
  
أن أعثر على شرٌك حٌاة      .3
      
العمل/أن أكون جٌدا فً المدرسة .4
  
أن أشفى   .5
      
أن ٌكون لدي أصدقاء  .6
  
.................. أمور أخرى 
 
 
 ماذا ٌعنً لك أن تكون مرٌض بالثلاسٌمٌا؟ 9.TR
 
     قلق دائم    .1
لا تستطٌع التأقلم   .2
  
 بعدم المقدرةالشعور  .3
الشعور بالضعؾ . 4  
      
  أبدا لست قلق .5
     
................... أمور أخرى
 
 
: الرجاء الاجابة على الأسئلة التالٌة ب
 لا 2نعم      1 
عر بأنك مختلؾ عن هل تش 01.TR
 عائلتك؟/أصدقائك
 
 
 
هل تعتقد أن الثلاسٌمٌا تؤثر على علاقتك  11.TR
 أختك؟/بأخٌك
 
 
 
 21.TR
 
هل تعتقد أن الثلاسٌمٌا تؤثر على علاقتك 
 بوالدٌك؟
 
 
 
 هل أنت متزوج ؟ 31.TR
 
 
 
 
 
 
 
اذا كانت الاجابة لا، حدد وضعك الاجتماعً 
 
 
 
  
 
 
 51.TR، انتقل الى سؤال اذا كانت اجابتك بنعم
 
 
  -------------------الوضع الاجتماعً هو 
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هل أنت قلق حول امكانٌتك إنشاء عائلة فً  41.TR
 المستقبل؟
 
 
 هل لدٌك وظٌفة؟ 51.TR
 
 
 هل سبق وكان لدٌك مشكلة فً التوظٌؾ؟ 61.TR
 
 
 
 
 
 
 
 71.TR
 
 
 ؟بشكل أساسً بمن تثق وتلجأ طالبا المساعدة
 
 
 
 
والدٌك     .1
أخوتك   . 2
أقرباء   . 3
   أصدقاء  . 4
طبٌب    .5
ممرضة    .6
   زوجة/زوج .7
دٌن   رجل .8
مجتمع الثلاسٌمٌا     .9
....................... آخر
 
 
 هل تتكلم حول مشاكلك وهمومك؟ 81.TR
 
أبدا   . 1
قلٌلا    .2
أحٌانا    .3
كثٌرا  .4
 
: ب الرجاء اجابة الاسئلة التالٌة
 لا 2نعم     1
 ؟المعنوي هل تظن أنك بحاجة الى المزٌد من الدعم 91.TR
 
 
هل قمت بالإنضمام الى مجموعات مساندة، مثل جمعٌة أصدقاء مرضى  02.TR
 الثلاسٌمٌا؟
 
 
 
 
 12.TR
 
 هل قام أحد بتعلٌق مزعج حول مرضك؟
 
 
 
 هل ٌعلم أصدقائك أو زملائك بأن لدٌك ثلاسٌمٌا؟ 22.TR
 
 
 
 مدرسك بأن لدٌك ثلاسٌمٌا؟/لكوهل ٌعلم مسؤ 32.TR
 
 
 هل تشعر بأنك صحً؟ 42.TR
 
 
 
: الرجاء الاجابة عن الاسئلة التالٌة ب
 دائما 6كثٌرا      4أحٌانا       3قلٌلا     2أبدا    1
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من مجتمعك؟  النفسً الذي تحتاجه/ المعنوي هل تشعر أنك تتلقى الدعم 1.LOQP
 
 
هل تشعر بالسعادة عندما تتلقى الدعم؟  2.LOQP
 
 
هل تشعر بأنك عبء على عائلتك ؟  3.LOQP
 
 
 4.LOQP
 
 
هل تعانً من اضطرابات فً النوم؟ 
 
 
 
هل تفكر فً وضعك المادي؟  5.LOQP
 
 
هل تشعر بعدم الأمان فً حٌاتك؟  6.LOQP
 
 
ؼلاقات من ك الى مركز العلاج بسبب الاهل ٌعٌق الاحتلال وصول 7.LOQP
؟  الحواجز أو الجدار
 
ؼاضب عندما لا تستطٌع أن تصل الى مركز / هل تشعر أنك مضطهد 8.LOQP
العلاج بسبب الاؼلاقات من قبل الاحتلال؟ 
 
 
  هل لدٌك قلق ان العلاج قد لا ٌتوفر فً اي لحظة تحتاجه؟ 9.LOQP
ر بأي لحظة؟ هل تشعر بعدم الأمان لعلمك أن العلاج قد لا ٌتوؾ 01.LOQP
 
   
 
هل تشعر بعدم السعادة لذهابك لمركز العلاج؟  11.LOQP
 
 
 
؟ ان تكون مرٌض ثلاسٌمٌا فً اي بلد اخرهل تفضل  21.LOQP
 
 
 ؟المعنوي هل تشعر أن معتقداتك الشخصٌة تمدك بالدعم 31.LOQP
 
 
 اذا كان الجواب نعم، لماذا؟
 
 
 
 ------------------------------
معنى؟  تهل تشعر بأن حٌاتك ذا 41.LOQP
 
 
  هل لدٌك الثقة فً أطبائك؟ 51.LOQP
هل تؤثر الٌة العلاج لازالة الحدٌد من الجسم عن طرٌق الدٌسفرال على  61.LOQP
 حٌاتك الاجتماعٌة؟
 
  هل لدٌك الموارد المالٌة الكافٌة لتلقً العلاج؟ 71.LOQP
  هل لدٌك الثقة فً علاجك؟ 81.LOQP
  
 831
هل تشعر بان الٌة العلاج لازالة الحدٌد من الجسم عن طرٌق الدٌسفرال  91.LOQP
 ٌجب ان تتؽٌر؟
 
 
: فقط لاستعمال الباحث المٌدانً
. الرجاء تعبئة الجدول التالً استنادا لاختٌارات المرضى للدواء أ أو الدواء ب فً كل من السٌنارٌوهات المقدمة لهم
لدواء ب االدواء أ رقم السٌنارٌو 
  السٌنارٌو الأول 
  السٌنارٌو الثانً 
  السٌنارٌو الثالث 
  السٌنارٌو الرابع 
  السٌنارٌو الخامس 
  السٌنارٌو السادس 
  السٌنارٌو السابع 
  السٌنارٌو الثامن 
  
: الرجاء الاجابة عن السؤالٌٌن التالٌٌن
ل الحصول على دواء هل أنت مستعد أن تدفع أي مبلػ من المال مقاب 1.ACD
ٌؤخذ عن طرٌق الفم بدل من الابرة؟ 
نعم . 1
لا . 2
 
اذا كان الجواب نعم، ما هو أكبر مبلػ من المال مستعد أن تدفعه مقابل  2.ACD
هذا العلاج الجدٌد بالشهر؟ 
 
شٌقل  -----------------------------
جدٌد 
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 :3 xidneppA
: السٌنارٌو الأول
ء أ الدواالخصائص  1
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  1
ط بشكل متوسٌقلل الحدٌد 
سهلة سهولة الٌة العلاج 
شدٌدة /كثٌرةالعوارض الجانبٌة 
 000,1) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
لا ٌوجد وجود ألم عند تلقً العلاج 
 
السٌنارٌو الثانً 
الدواء أ الخصائص  2
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة لعلاج سهولة الٌة ا
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  2
بشكل فعال ٌقلل الحدٌد 
سهلة سهولة الٌة العلاج 
شدٌدة /كثٌرةة العوارض الجانبً
 0) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
  
 041
السٌنارٌو الثالث 
الدواء أ الخصائص  3
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  3
بشكل فعال ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,1) قل جدٌدشً(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
لا ٌوجد وجود ألم عند تلقً العلاج 
 
السٌنارٌو الرابع 
الدواء أ الخصائص  4
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  4
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا ٌاة الٌومٌة بشكل طبٌعً القدرة على ممارسة الح
لا ٌوجد وجود ألم عند تلقً العلاج 
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السٌنارٌو الخامس 
الدواء أ الخصائص  5
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم بشكل طبٌعً  القدرة على ممارسة الحٌاة الٌومٌة
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  5
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,1) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل طفٌؾ ند تلقً العلاج وجود ألم ع
 
السٌنارٌو السادس 
الدواء أ الخصائص  6
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر لعلاج وجود ألم عند تلقً ا
 
الدواء ب الخصائص  6
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 005,1) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل طفٌؾ وجود ألم عند تلقً العلاج 
 
 
  
 241
و السابع السٌناري
الدواء أ الخصائص  7
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
ب الدواء الخصائص  7
بشكل متوسط ٌقلل الحدٌد 
سهلة سهولة الٌة العلاج 
شدٌدة /كثٌرةالعوارض الجانبٌة 
 005,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل طفٌؾ وجود ألم عند تلقً العلاج 
 
السٌنارٌو الثامن 
الدواء أ الخصائص  8
بشكل متوسط ٌقلل الحدٌد 
ؼٌر سهلة سهولة الٌة العلاج 
خفٌفة /قلٌلةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
نعم القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل كبٌر وجود ألم عند تلقً العلاج 
 
الدواء ب الخصائص  8
بشكل فعال ٌقلل الحدٌد 
ؼٌر سهلة لاج سهولة الٌة الع
شدٌدة /كثٌرةالعوارض الجانبٌة 
 000,2) شٌقل جدٌد(تكالٌف الدواء فً الشهر 
لا القدرة على ممارسة الحٌاة الٌومٌة بشكل طبٌعً 
بشكل طفٌؾ وجود ألم عند تلقً العلاج 
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Appendix 4: 
Multipliers applied for the clinical features asked in the questionnaire under the 
clinical burden section. 
Question 
Code 
Clinical Feature Multiplier to be applied 
CL1 Transfusion 3 
CL2 Desferal 3 
CL5 Spleen 1 
CL10 Infections 1 
CL14 Hospital admissions 1 
CL11 Growth 2 
CL6 Facial deformity 2 
CL12 Sexual dysfunction 3 
CL7 Bone, Joint pain 1.5 
CL8 Fractures 1 
CL3 Leg Ulcers 2 
CL13 Mobility 2 
CL9 Deafness 1 
CL4 Gallstones 1 
CL18 Thyroid, parathyroid 1 
CL17 Cardiac 4 
CL15 Liver 1 
CL16 Diabetes 1.5 
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